# Sugarfit GLP-1 Glossary: Clear, India-Relevant Health Terms This glossary explains important GLP-1, metabolic-health, nutrition, exercise and treatment-safety terms in plain language for readers in India. It is educational and does not replace an individual clinical assessment. ## Featured glossary guides - [GLP-1](/what-is-glp-1-and-how-does-it-work) - [GLP-1 receptor agonist](/glossary/glp-1-receptor-agonist) - [GIP](/glossary/gip) - [Obesity management medication](/glossary/obesity-management-medication) - [Obesity](/glossary/obesity) - [Central obesity](/glossary/central-obesity) - [Abdominal obesity](/glossary/abdominal-obesity) - [Fasting plasma glucose](/glossary/fasting-plasma-glucose) - [HbA1c](/glossary/hba1c) - [Hypoglycaemia](/glossary/hypoglycaemia) - [Hunger changes during GLP-1 treatment](/glossary/hunger) - [Appetite changes during GLP-1 treatment](/glossary/appetite) - [Ghrelin](/glossary/ghrelin) - [Portion control during GLP-1 treatment](/glossary/portion-control) - [Balanced plate for GLP-1 nutrition](/glossary/balanced-plate) - [Dehydration](/glossary/dehydration) - [Acid reflux](/glossary/acid-reflux) - [Gallstones](/glossary/gallstones) - [Gallbladder disease](/glossary/gallbladder-disease) - [Lipid profile](/glossary/lipid-profile) - [Liver function test (LFT)](/glossary/liver-function-test-lft) - [Kidney function test (KFT)](/glossary/kidney-function-test-kft) - [CDSCO](/glossary/cdsco) - [Drug approval in India](/glossary/drug-approval-in-india) - [Dual GIP/GLP-1 receptor agonist](/glossary/dual-gip-glp-1-receptor-agonist) - [Visceral fat](/glossary/visceral-fat) - [Continuous glucose monitoring (CGM)](/glossary/continuous-glucose-monitoring-cgm) - [Food cravings during GLP-1 treatment](/glossary/craving) - [Protein intake during GLP-1 treatment](/glossary/high-protein-diet) - [Pancreatitis](/glossary/pancreatitis) - [Serum creatinine](/glossary/serum-creatinine) - [GLP-1 medicine availability in India](/glossary/medicine-availability-in-india) - [Gastric emptying](/glossary/gastric-emptying) - [Waist circumference](/glossary/waist-circumference) - [Insulin](/glossary/insulin) - [Food noise](/glossary/food-noise) - [Vegetarian diet](/glossary/vegetarian-diet) - [Gastroparesis](/glossary/gastroparesis) - [EGFR test](/glossary/egfr-test) - [Satiety](/glossary/satiety) - [Indian waist circumference cut-offs](/glossary/indian-waist-circumference-cut-offs) - [Oral glucose tolerance test (OGTT)](/glossary/oral-glucose-tolerance-test-ogtt) - [Fullness](/glossary/fullness) - [Indian vegetarian protein](/glossary/indian-vegetarian-protein) - [Delayed gastric emptying](/glossary/delayed-gastric-emptying) - [Thyroid function test](/glossary/thyroid-function-test) - [Tirzepatide in India](/glossary/tirzepatide-in-india) - [Postprandial glucose](/glossary/postprandial-glucose) - [Body composition](/glossary/body-composition) - [Microvascular complications](/glossary/microvascular-complications) - [Emotional eating](/glossary/emotional-eating) - [Nuts and seeds](/glossary/nuts-and-seeds) - [Kidney injury](/glossary/kidney-injury) - [Body composition analysis](/glossary/body-composition-analysis) - [Glucose-dependent insulin secretion](/glossary/glucose-dependent-insulin-secretion) - [Lean body mass](/glossary/lean-body-mass) - [Macrovascular complications](/glossary/macrovascular-complications) - [Protein](/glossary/protein) - [Resistance training](/glossary/resistance-training) - [Pregnancy](/glossary/pregnancy) - [Urine albumin-creatinine ratio](/glossary/urine-albumin-creatinine-ratio) - [Metabolic syndrome](/glossary/metabolic-syndrome) - [Breastfeeding](/glossary/breastfeeding) - [Bioelectrical impedance analysis](/glossary/bioelectrical-impedance-analysis) - [Liraglutide](/glossary/liraglutide) - [Sarcopenia](/glossary/sarcopenia) - [Weight-Loss Plateau](/glossary/weight-loss-plateau) - [Cardiometabolic Risk](/glossary/cardiometabolic-risk) - [Hypertension](/glossary/hypertension) - [Plant Protein During GLP-1 Treatment](/glossary/plant-protein) - [Dal During GLP-1 Treatment](/glossary/dal) - [Walking During GLP-1 Treatment](/glossary/walking) - [Muscle Preservation During GLP-1 Weight Loss](/glossary/muscle-preservation) - [Surgery, Anaesthesia and GLP-1 Medicines](/glossary/surgery-and-anaesthesia) - [Red-Flag Symptoms During GLP-1 Treatment](/glossary/red-flag-symptom) - [Obesity Assessment](/glossary/obesity-assessment) - [PCOS and Insulin Resistance](/glossary/pcos-and-insulin-resistance) - [Indian Obesity Guidelines](/glossary/indian-obesity-guidelines) - [Vegetarian Diet During GLP-1 Treatment](/glossary/vegetarian-diet-on-glp-1) ## More health terms explained ### GLP-1 receptor The GLP-1 receptor is a protein on the surface of certain cells that receives the GLP-1 signal. Activation of this receptor can support glucose-dependent insulin release, reduce glucagon, slow digestion and influence appetite. Natural GLP-1 and GLP-1 receptor agonist medicines both use this pathway, but medicines are longer-acting and have product-specific effects and risks. **What this means in India:** The receptor explains how the pathway works, but each medicine can have different approved uses in India. **How this relates to GLP-1 care:** It is the main target of GLP-1 receptor agonist medicines. **Safety and when to seek help:** Medicine effects and warnings are product-specific. The receptor mechanism alone does not establish whether a medicine is suitable for someone. **Is the receptor itself a medicine?** No. It is a protein in the body; medicines activate it. ### Prescription medicine A prescription medicine is a medicine that should be supplied and used under an authorised prescriber's direction. In India, Schedule H, H1 and X medicines carry specific prescription and dispensing controls. Prescription status signals the need for professional assessment and monitoring; it does not mean a medicine is suitable for every person with the relevant condition. **What this means in India:** Prescription status can differ between countries, so the current Indian label and Drugs Rules are the relevant references. **How this relates to GLP-1 care:** GLP-1 medicines used for diabetes or weight management require medical supervision and authorised supply. **Safety and when to seek help:** Do not share, resell, self-start or independently change prescription medicines. **Does a prescription make a medicine automatically safe?** No. It means a qualified prescriber must assess suitability and monitoring needs. ### Generic medicine A generic medicine is generally intended to match an established reference medicine in active ingredient and relevant performance and quality requirements under the applicable regulator. A generic medicine is not the same thing as a generic name: the generic or nonproprietary name identifies the active substance, while an approved product may still be sold under a brand. **What this means in India:** In India, approval, manufacturer, strength, dosage form and authorised supply chain all matter; approval overseas does not establish approval in India. **How this relates to GLP-1 care:** Complex injectable or device-based products should not be assumed interchangeable solely because a molecule name matches. **Safety and when to seek help:** Do not substitute products or devices without the prescriber or pharmacist, especially for injectable medicines. **Is every product with the same molecule interchangeable?** No. Strength, formulation, device, indication and regulatory approval also matter. ### Class I obesity Class I obesity is a BMI category, but its numerical range depends on the classification system. The global WHO adult system commonly uses 30.0–34.9 kg/m². Some Asian Indian clinical classifications use lower thresholds and may label 25.0–29.9 kg/m² as obesity grade or class I. Because classification systems differ, the stated BMI range should always identify which system it uses. **What this means in India:** Indian public-health screening commonly identifies obesity from BMI 25 kg/m², but the exact class labels can vary by guideline. **How this relates to GLP-1 care:** BMI category alone does not establish GLP-1 medicine eligibility; comorbidities, history and the Indian product label matter. **Safety and when to seek help:** BMI is a screening tool, not a complete diagnosis of individual health or body composition. **Why can two reports give different obesity classes?** They may be using global versus South Asian or Indian thresholds. ### Adipocyte An adipocyte is a specialised cell in adipose tissue that stores energy mainly as triglycerides. Adipocytes also release signalling molecules that help regulate appetite, insulin sensitivity, inflammation and energy balance. They are active metabolic cells, not inert storage bags, and different adipose depots can have different health effects. **What this means in India:** There is no separate India-specific threshold for adipocytes, and they cannot be counted or felt directly in routine care. **How this relates to GLP-1 care:** Weight-management treatment can change adipose-tissue mass and metabolic signals, but routine GLP-1 care does not measure individual adipocytes. **Safety and when to seek help:** Do not use the term to diagnose metabolic disease without clinical measurements. **Is an adipocyte the same as body fat?** It is one cell type within adipose tissue; body fat includes many cells and structures. ### Diabetic ketoacidosis Diabetic ketoacidosis is a life-threatening emergency caused by severe insulin deficiency, leading to high ketones and dangerous blood acidity. Symptoms may include extreme tiredness, nausea, vomiting, abdominal pain, dehydration, deep or difficult breathing, fruity-smelling breath and fainting. It most often affects type 1 diabetes but can occur in type 2 diabetes. **What this means in India:** Suspected DKA needs emergency evaluation and should not be managed through online advice. **How this relates to GLP-1 care:** DKA is not the same as nutritional ketosis. People with diabetes who are unwell need their clinician's sick-day and ketone-testing plan, regardless of GLP-1 use. **Safety and when to seek help:** Suspected DKA requires immediate emergency medical care. **Is DKA just very high blood sugar?** No. It involves ketone accumulation and acidosis and can be life-threatening. ### Obstructive sleep apnoea Obstructive sleep apnoea is a sleep disorder in which the upper airway repeatedly narrows or closes during sleep, interrupting breathing. Loud snoring, gasping, witnessed pauses, morning headache and daytime sleepiness are common clues. Diagnosis generally requires clinical assessment and a sleep study; snoring alone does not confirm the condition. **What this means in India:** Severe daytime sleepiness can make driving or work unsafe and warrants an appropriate sleep evaluation. **How this relates to GLP-1 care:** OSA is associated with obesity and cardiometabolic risk. Weight management may help some people, but it does not replace prescribed airway treatment or follow-up. **Safety and when to seek help:** Breathing pauses and severe daytime sleepiness warrant prompt assessment; avoid driving if sleepiness makes it unsafe. **Does everyone who snores have OSA?** No. A clinical assessment and usually a sleep study are needed. ### Binge eating Binge eating describes episodes of eating an unusually large amount of food with a sense of loss of control. Binge-eating disorder involves recurrent episodes and significant distress and requires assessment by a qualified health or mental-health professional. It is not simply overeating occasionally, and it should not be treated with shame or restrictive punishment. **What this means in India:** Support should use non-stigmatising language and, where needed, culturally appropriate mental-health or eating-disorder care. **How this relates to GLP-1 care:** Appetite change during weight treatment does not by itself treat the emotional, behavioural and mental-health dimensions of binge-eating disorder. **Safety and when to seek help:** Seek professional help for recurrent loss-of-control eating, purging, severe restriction, depression or self-harm thoughts. **Is every large meal a binge?** No. Loss of control, recurrence and distress are important distinctions. ### Legumes Legumes are plants in the pea and bean family. Their edible seeds include lentils, chickpeas, beans and peas; dried edible seeds are often called pulses. They can provide plant protein, carbohydrate, fibre and micronutrients. In Indian meals, dal, rajma, chana and many regional pulses are familiar examples. **What this means in India:** Portion size, preparation, oil and accompaniments change the nutritional profile of a meal, so dal is not automatically low-calorie. **How this relates to GLP-1 care:** Fibre- and protein-containing foods may support meal quality and fullness during GLP-1 care, but individual tolerance and nutrition needs vary. **Safety and when to seek help:** People with digestive symptoms, allergies or kidney-related dietary restrictions need individual advice. **Are pulses and legumes identical?** Pulses are the dried edible seeds of legume plants; legumes is the broader plant family. ### Refined carbohydrate A refined carbohydrate usually refers to a grain or carbohydrate-rich food that has been processed to remove parts such as bran and germ, often reducing fibre and some micronutrients. Examples can include refined flour products and polished grains. The term is not identical to sugar, and processing level and the whole meal both matter. **What this means in India:** Maida is refined flour; rice varieties and preparation methods differ. Portion size and the overall meal matter more than labelling a food simply good or bad. **How this relates to GLP-1 care:** People experiencing early fullness on GLP-1 treatment may benefit from prioritising nutrient-dense foods, but rigid carbohydrate bans are not required for everyone. **Safety and when to seek help:** Diabetes meal planning and carbohydrate changes should account for glucose-lowering medicines and hypoglycaemia risk. **Are refined carbohydrates the same as added sugar?** No. Added sugar is one type of carbohydrate; refined grains may contain mostly starch. ### Aerobic exercise Aerobic exercise is planned, repetitive activity that uses large muscle groups and raises breathing and heart rate for a sustained period. Brisk walking, cycling, swimming and dancing are common examples. WHO recommends regular aerobic activity alongside muscle-strengthening work, adjusted for age, ability, health and current fitness. **What this means in India:** Walking, cycling, swimming and dance can be adapted to climate, air quality, access and personal safety. **How this relates to GLP-1 care:** Aerobic activity supports cardiovascular fitness and metabolic health during weight-management care; it complements rather than replaces nutrition, strength work or prescribed treatment. **Safety and when to seek help:** People with concerning chest pain, fainting, severe breathlessness or unstable medical conditions need assessment before continuing exercise. **Is walking aerobic exercise?** Brisk walking can be aerobic when it raises breathing and heart rate to an appropriate intensity. ### VO₂ max VO₂ max is the highest rate at which the body can take in and use oxygen during intense exercise. It is a measure of cardiorespiratory fitness and may be measured in a laboratory or estimated by fitness tests and devices. Values depend on age, sex, body size, training, health and test method. **What this means in India:** Consumer wearables provide estimates, not diagnoses; compare trends only when device and test conditions are similar. **How this relates to GLP-1 care:** VO₂ max can improve with training even when weight changes slowly. It is not a standard test of GLP-1 response. **Safety and when to seek help:** Maximal exercise testing should be supervised when medical history or symptoms raise concern. **Is a smartwatch VO2 max exact?** No. It is an estimate based on device algorithms and available sensor data. ### MEN2 MEN2 is an inherited syndrome, usually caused by a pathogenic RET gene variant, that greatly increases the risk of medullary thyroid carcinoma and can involve adrenal pheochromocytoma and parathyroid disease. It is not ordinary thyroid disease. Diagnosis and family screening require specialist genetic and endocrine care. **What this means in India:** Anyone with a personal or family history of MEN2 or medullary thyroid carcinoma should tell their clinician before medicine assessment. Product warnings should be checked against current Indian prescribing information. **How this relates to GLP-1 care:** Some GLP-1 medicine labels contain specific contraindications or warnings involving MEN2 or medullary thyroid carcinoma. Because these warnings differ by product, the current label for the specific medicine matters. **Safety and when to seek help:** People with suspected MEN2 or a relevant family history need specialist assessment; do not use an online glossary to decide medicine safety. **Is MEN2 the same as hypothyroidism?** No. MEN2 is an inherited tumour-predisposition syndrome involving endocrine glands. ### DEXA scan A DEXA or DXA scan uses low-dose X-rays to measure bone mineral density, usually at the hip and spine. Some scanners can also estimate body composition, but bone-density and body-composition reports answer different questions. A scan is ordered according to age, fracture risk, medical history and treatment monitoring needs. **What this means in India:** Before a scan, confirm whether it is for bone density or whole-body composition, because the reports answer different questions and require clinical interpretation. **How this relates to GLP-1 care:** DEXA is not routinely required solely because someone uses a GLP-1 medicine, but bone and lean-mass health may matter in broader weight-management assessment. **Safety and when to seek help:** Inform the imaging centre about pregnancy possibility and follow local preparation instructions. **Does DEXA directly measure every type of body fat?** No. It estimates tissue compartments and results depend on the scan protocol and machine. ### Clinical assessment A clinical assessment is a structured evaluation that combines the person's concerns, medical and medicine history, symptoms, examination and relevant tests to guide diagnosis and care. In weight management it may include BMI and waist measures, blood pressure, glucose and lipids, sleep, eating patterns, mental health, reproductive plans and treatment preferences. **What this means in India:** India-relevant thresholds, current medicine indications, access and monitoring requirements should be considered during assessment. **How this relates to GLP-1 care:** A clinical assessment is required before deciding whether a GLP-1 medicine is suitable and while monitoring benefit, side effects and ongoing need. **Safety and when to seek help:** An online form or BMI calculator cannot replace examination and individual medical review when medicine is being considered. **Is a blood test alone a clinical assessment?** No. Tests are interpreted alongside history, symptoms, examination and goals. ### Non-response Non-response means a treatment has not produced the agreed clinically meaningful benefit after an adequate, correctly used trial. The definition depends on the condition, medicine, dose stage, duration and outcomes being monitored. For obesity care, response includes more than one early weight reading and may include health, tolerability and adherence. **What this means in India:** Treatment response should be reviewed at the clinician-agreed point using the current Indian product label; overseas stopping rules do not automatically apply in India. **How this relates to GLP-1 care:** Before labelling GLP-1 treatment a non-response, clinicians may review dose progression, duration, adherence, injection technique, other medicines, nutrition, sleep, underlying conditions and whether goals were realistic. **Safety and when to seek help:** Do not increase dose, combine products or abruptly stop treatment in response to a plateau without the prescriber. **Is a short weight plateau non-response?** Not necessarily. Response must be judged over an adequate period using agreed outcomes and the correct treatment stage. ### Perimenopause weight gain Perimenopause is the transition leading up to menopause, when hormone levels and menstrual patterns change. Some women notice weight gain or a shift toward more abdominal fat during this life stage, but ageing, reduced muscle mass, sleep disruption, activity, medicines and other health conditions can also contribute. **What this means in India:** Assessment may include menstrual history, symptoms, medicines, thyroid or metabolic concerns and reproductive potential, because weight change should not automatically be attributed to hormones. **How this relates to GLP-1 care:** A GLP-1 medicine is not a treatment for perimenopause itself. Weight-management eligibility and safety require separate assessment, including pregnancy possibility and the product-specific label. **Safety and when to seek help:** Seek assessment for very heavy or unexpected bleeding, rapid unexplained weight change, severe pelvic symptoms, pregnancy possibility or significant mood symptoms. **Does perimenopause always cause weight gain?** No. Experiences vary, and several age-related, behavioural and medical factors may contribute. - [NIDDK: Insulin, medicines and other diabetes treatments](https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments) - [NIDDK: Gallstones](https://www.niddk.nih.gov/health-information/digestive-diseases/gallstones) - [NIDDK: Food portions](https://www.niddk.nih.gov/health-information/weight-management/just-enough-food-portions) - [CDSCO: New drugs](https://cdsco.gov.in/opencms/opencms/en/Drugs/New-Drugs/) - [CDSCO: Drugs Rules](https://www.cdsco.gov.in/opencms/opencms/en/Acts-and-rules/Drugs-Rules/) - [WHO: International Nonproprietary Names](https://www.who.int/teams/health-product-and-policy-standards/inn) - [WHO: Obesity and overweight](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight) - [WHO South-East Asia: Diabetes diagnostic criteria](https://cdn.who.int/media/docs/default-source/cardiovascular-diseases/booklet-know-your-cardiovascular-disease-risk-take-action.pdf) - [WHO: Physical activity and sedentary behaviour guidelines](https://www.who.int/publications/i/item/9789240014886) - [WHO: Care for women with diabetes during pregnancy](https://www.who.int/publications/b/81691) - [WHO: Obesity and GLP-1 therapies](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) - [WHO: Safe and appropriate use of GLP-1 receptor agonists](https://www.who.int/news/item/30-07-2026-statement-from-the-joint-meeting-of-the-advisory-committee-on-safety-of-medicinal-products-%28acsomp%29-and-the-global-advisory-committee-on-vaccine-safety-%28gacvs%29-on-the-safe-and-appropriate-use-of-glp-1-receptor-agonists) - [MoHFW: Standard treatment guidance describing abdominal obesity](https://www.clinicalestablishments.mohfw.gov.in/sites/default/files/standard-treatment-guidelines/5191.pdf) - [ICMR-NIN: Dietary Guidelines for Indians 2024](https://www.nin.res.in/dietaryguidelines/pdfjs/locale/DGI07052024P.pdf) - [NIAMS: Osteoarthritis](https://www.niams.nih.gov/health-topics/osteoarthritis) - [MedlinePlus: Liver function tests](https://medlineplus.gov/lab-tests/liver-function-tests/) - [NIDDK: The A1C test and diabetes](https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test) - [NIDDK: Identify and evaluate chronic kidney disease](https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/kidney-disease/identify-manage-patients/evaluate-ckd) - [ICMR-NIN: Dietary Guidelines for Indians 2024](https://www.nin.res.in/dietaryguidelines/pdfjs/locale/DGI07052024P.pdf) - [WHO: Healthy diet](https://www.who.int/news-room/fact-sheets/detail/healthy-diet) - [CDSCO: Approved new drugs](https://www.cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/) - [American Society of Anesthesiologists: GLP-1 medicines before surgery](https://madeforthismoment.asahq.org/preparing-for-surgery/risks/drugs-diabetes-weight-loss/) - [ICMR: Handbook on national ethical guidelines](https://www.icmr.gov.in/icmrobject/uploads/Guidelines/1724914217_handbook_on_icmr_ethical_guidelines_2018.pdf) - [NIDDK: Continuous glucose monitoring](https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes/continuous-glucose-monitoring) - [NIDDK: Pancreatitis symptoms and causes](https://www.niddk.nih.gov/health-information/digestive-diseases/pancreatitis/symptoms-causes) - [NIDDK: Kidney disease evaluation](https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/kidney-disease/identify-manage-patients/evaluate-ckd) - [ICMR-NIN: Dietary Guidelines for Indians 2024](https://www.nin.res.in/dietaryguidelines/pdfjs/locale/DGI07052024P.pdf) - [WHO: Physical activity](https://www.who.int/news-room/fact-sheets/detail/physical-activity) - [WHO India: Diabetes](https://www.who.int/india/health-topics/diabetes) - [CDSCO: Approved new drugs](https://www.cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/) - [NIDDK: Diabetes and insulin](https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes) - [NIDDK: Gastroparesis](https://www.niddk.nih.gov/health-information/digestive-diseases/gastroparesis) - [NIDDK: Diabetes and prediabetes tests](https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/diabetes/diabetes-prediabetes) - [NIDDK: Kidney disease tests](https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/tests-diagnosis) - [NIDDK: Thyroid tests](https://www.niddk.nih.gov/-/media/Files/Diagnostic-Tests/thyroidtests_508.pdf) - [ICMR-NIN: Dietary Guidelines for Indians 2024](https://www.nin.res.in/dietaryguidelines/pdfjs/locale/DGI07052024P.pdf) - [MoHFW: Waist circumference](https://aam.mohfw.gov.in/download/document/b09f1edf31a9165aebf486a55bbe54f5.pdf) - [WHO: Obesity and GLP-1 therapies](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) - [CDSCO: Approved new drugs](https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/) - [PIB: GLP-1 supply-chain surveillance](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2244252&lang=1®=1) - [PubMed: Food noise definition](https://pubmed.ncbi.nlm.nih.gov/40628707/) - [NIDDK: Diabetes and insulin](https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes) - [NIDDK: Diabetes and prediabetes tests](https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/diabetes/diabetes-prediabetes) - [NIDDK: Assess urine albumin](https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/kidney-disease/identify-manage-patients/evaluate-ckd/assess-urine-albumin) - [CDC: Diabetes complications](https://www.cdc.gov/diabetes/prevention-type-2/stop-diabetes-complications.html) - [WHO: Obesity and GLP-1 therapies](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) - [WHO: GLP-1 safety statement](https://www.who.int/news/item/30-07-2026-statement-from-the-joint-meeting-of-the-advisory-committee-on-safety-of-medicinal-products-%28acsomp%29-and-the-global-advisory-committee-on-vaccine-safety-%28gacvs%29-on-the-safe-and-appropriate-use-of-glp-1-receptor-agonists) - [WHO: Physical activity](https://www.who.int/news-room/fact-sheets/detail/physical-activity) - [ICMR-NIN: Dietary Guidelines for Indians 2024](https://www.nin.res.in/dietaryguidelines/pdfjs/locale/DGI07052024P.pdf) - [CDSCO: Approved new drugs](https://cdsco.gov.in/opencms/en/Approval_new/Approved-New-Drugs/) - [NPPA: Pharma Sahi Daam](https://www.nppaindia.nic.in/pharma_sahi_daam) - [Government of India: GLP-1 supply-chain surveillance](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2244252&lang=1®=1) - [WHO: Obesity and GLP-1 therapies](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) - [CDSCO: Approved new drugs](https://cdsco.gov.in/opencms/en/Approval_new/Approved-New-Drugs/) - [ICMR-NIN: Dietary Guidelines for Indians 2024](https://www.nin.res.in/dietaryguidelines/pdfjs/locale/DGI07052024P.pdf) - [WHO: Physical activity](https://www.who.int/news-room/fact-sheets/detail/physical-activity) - [NIH/NHLBI: Metabolic syndrome](https://www.nhlbi.nih.gov/health/metabolic-syndrome) - [NIH: Bioelectrical impedance assessment](https://pubmed.ncbi.nlm.nih.gov/8780375/) - [India Telemedicine Practice Guidelines](https://esanjeevani.mohfw.gov.in/assets/guidelines/Telemedicine_Practice_Guidelines.pdf) - [Joint advisory: Nutritional priorities during GLP-1 therapy](https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) - [FDA: Wegovy prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s023lbl.pdf) - [FDA: Rybelsus prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf) *Educational information only. It does not diagnose a condition, establish treatment eligibility or replace advice from a qualified healthcare professional.* ### Incretin An incretin is a gut hormone released after eating that helps the pancreas respond to glucose. GLP-1 and GIP are the best-known incretins. The term also appears in ‘incretin-based medicines’, which includes different prescription classes and should not be used as though every medicine works identically. **What this means in India:** The biological definition is universal, while medicine indications and authorised products must be checked in current Indian information. **How this relates to GLP-1 care:** Natural GLP-1 is an incretin, and a [GLP-1 receptor agonist](/glossary/glp-1-receptor-agonist) acts on one incretin pathway for longer. **Safety and when to seek help:** A mechanism name does not establish personal treatment suitability or medicine approval. **Are incretins medicines?** Incretins are natural hormones; incretin-based medicines are treatments designed around those pathways. ### Generic name A generic or nonproprietary name identifies a medicine's active substance independently of a company's brand name. WHO's International Nonproprietary Name system provides globally recognised names, but a shared generic name does not make every formulation, strength or device interchangeable. **What this means in India:** Check the exact product's Indian approval, manufacturer, strength, dosage form and authorised supply channel; a generic name alone is not proof of approval. **How this relates to GLP-1 care:** GLP-1 medicines should be discussed by molecule as well as brand so the product and indication are clear. See [CDSCO](/glossary/cdsco). **Safety and when to seek help:** Do not switch injections, devices or formulations only because the generic name appears similar. **Is a generic name the same as a generic medicine?** No. The name identifies the active substance; a generic medicine is a regulated product. ### Medicine storage Medicine storage means keeping a product under the temperature, light, moisture, packaging and handling conditions stated on its label. Requirements can differ before first use and after opening, and refrigeration does not automatically mean freezing is safe. **What this means in India:** Heat and power interruptions can make storage planning important. Follow the Indian pack and pharmacist's instructions for the exact product and ask what to do after an excursion. **How this relates to GLP-1 care:** Some GLP-1 products need temperature-controlled storage, but conditions vary by product and formulation. **Safety and when to seek help:** Do not use a product that was frozen, overheated, damaged or stored outside its instructions until a pharmacist or manufacturer confirms it remains suitable. **Can every injectable medicine be stored the same way?** No. Use the exact product label rather than a general rule. ### Class II obesity Class II obesity is a BMI category whose numerical range depends on the classification system. In the global WHO adult system it commonly means a BMI of 35.0–39.9 kg/m². Indian or Asian classification systems may use lower thresholds or different class labels, so the source system must be named. **What this means in India:** Indian health risk can occur at lower BMI values, but class terminology is not completely uniform across guidance. **How this relates to GLP-1 care:** BMI class can inform assessment but does not by itself establish medicine eligibility. Read the broader [obesity](/glossary/obesity) guide. **Safety and when to seek help:** BMI is a screening measure and should be interpreted with waist, metabolic health, function and medical history. **Why might two clinicians use different class ranges?** They may be using different global, Asian or Indian classification systems. ### Set point theory Set point theory proposes that biological feedback systems defend body weight or body-fat stores around a range by changing hunger, energy expenditure and other signals after weight loss or gain. It is a model, not a directly measurable personal number, and human weight is also influenced by environment, behaviour, illness and medicines. **What this means in India:** The theory does not create a separate Indian target or prove that weight cannot change. **How this relates to GLP-1 care:** It can help explain why hunger or weight regain may occur, but it does not predict an individual's response to GLP-1 treatment. **Safety and when to seek help:** Do not use the theory to justify unsafe restriction, unprescribed dose changes or hopelessness about treatment. **Can a test reveal my set point?** No validated routine test provides a person's exact set point. ### Ketosis Ketosis is a metabolic state in which the body produces more ketones because carbohydrate availability or insulin action is reduced and fat is being used as fuel. Mild nutritional ketosis is not the same as diabetic ketoacidosis, which involves dangerous acidity and is a medical emergency. **What this means in India:** Ketone units, testing methods and sick-day plans should be confirmed with the treating diabetes team. **How this relates to GLP-1 care:** Reduced intake, illness and diabetes medicines can change metabolic risk; GLP-1 treatment does not make emergency symptoms safe to ignore. **Safety and when to seek help:** Vomiting, abdominal pain, deep or difficult breathing, marked drowsiness or high ketones need urgent medical assessment, especially in diabetes. **Is ketosis always dangerous?** No, but it must be distinguished from diabetic ketoacidosis and interpreted in context. ### Osteoarthritis Osteoarthritis is a joint disease in which cartilage and other joint tissues change and break down over time. It commonly affects the knees, hips, hands and spine and can cause pain, stiffness, swelling and reduced movement. It is not simply normal wear and tear. **What this means in India:** Assessment should consider mobility, work, access to physiotherapy, pain management and other health conditions. **How this relates to GLP-1 care:** Weight management may reduce load on some joints, but a GLP-1 medicine does not replace osteoarthritis assessment, exercise or other indicated treatment. **Safety and when to seek help:** Sudden hot swelling, fever, inability to bear weight or major injury needs prompt medical review. **Does weight loss cure osteoarthritis?** No. It may improve symptoms for some weight-bearing joints, but joint disease still needs appropriate care. ### Portion size Portion size is the amount of food or drink a person chooses to consume at one time. It may be larger or smaller than the serving size shown on a package or used in a nutrition guide. **What this means in India:** Katoris, ladles, rotis, packets and restaurant servings vary, so household measures can improve consistency without creating a universal prescription. **How this relates to GLP-1 care:** Earlier fullness can change portions during GLP-1 care. The [portion control](/glossary/portion-control) guide explains how to adapt without severe restriction. **Safety and when to seek help:** People with diabetes, kidney disease, pregnancy or eating-disorder risk may need individual portion guidance. **Is a labelled serving a recommended portion?** Not necessarily. It is a reference amount, not a personalised recommendation. ### Greek yoghurt Greek yoghurt is yoghurt that has been strained or otherwise processed to make it thicker and usually more concentrated in protein than regular yoghurt. Protein, fat, added sugar and live-culture content vary substantially between products. **What this means in India:** Compare the ingredient list and nutrition panel; dahi and Greek yoghurt are not nutritionally identical simply because both are cultured milk products. **How this relates to GLP-1 care:** It can be one protein-containing food option during GLP-1 care when tolerated, but it is not required and portions should fit the overall diet. **Safety and when to seek help:** People with milk allergy should avoid dairy yoghurt; lactose tolerance and kidney-related protein advice vary. **Is every Greek yoghurt unsweetened?** No. Flavoured products can contain added sugar, so check the label. ### Added sugar Added sugar is sugar introduced during preparation, processing or at the table rather than sugar naturally present within intact fruit or plain milk. Ingredient names vary, and total sugar on a label can include both naturally occurring and added sugars. **What this means in India:** Added sugar may appear in sweets, drinks, packaged foods, sauces and sweetened dairy products. Use the ingredient list and nutrition information instead of judging by taste alone. **How this relates to GLP-1 care:** Limiting heavily sweetened, nutrient-poor foods may support metabolic care, but GLP-1 treatment does not require a universal zero-sugar diet. **Safety and when to seek help:** Carbohydrate changes should account for glucose-lowering medicines and [hypoglycaemia](/glossary/hypoglycaemia) risk. **Is fruit sugar considered added sugar?** Sugar naturally present inside whole fruit is not added sugar; sugar added to a fruit product is. ### Steps per day Steps per day is a simple measure of ambulatory activity recorded by a phone, pedometer or wearable. It can help track personal movement trends, but device counts vary and there is no universal 10,000-step requirement for every person. **What this means in India:** Walking plans should account for heat, air quality, road safety, footwear, work patterns and access to suitable spaces. **How this relates to GLP-1 care:** More daily movement can support fitness and metabolic health during GLP-1 care, alongside strength work and adequate nutrition. **Safety and when to seek help:** New chest pain, fainting, severe breathlessness or injury needs medical assessment; increase activity gradually when starting from a low level. **Must everyone reach 10,000 steps?** No. A safe, progressive goal based on current ability is more useful than one universal target. ### Flexibility Flexibility is the ability of a joint or group of joints to move through an available range of motion. It is influenced by muscles, tendons, joint structure, age, activity and injury. Flexibility is different from strength, balance and aerobic fitness. **What this means in India:** Yoga and stretching may support flexibility, but exercises should be adapted to health, pain and ability rather than assuming every pose is safe. **How this relates to GLP-1 care:** Flexibility work may support comfortable movement during weight management, but it does not replace resistance or aerobic activity. **Safety and when to seek help:** Stop and seek advice for sharp pain, new weakness, numbness or instability; avoid forcing a painful range. **Is flexibility the same as mobility?** No. Mobility also includes strength, control and the ability to use a range of motion. ### Preconception Preconception is the period before pregnancy. Preconception care reviews health conditions, medicines, nutrition, vaccinations, reproductive plans and other factors that can affect the person and a future pregnancy. **What this means in India:** Discuss pregnancy plans early with the treating clinician so Indian product information, access and referral pathways can be reviewed. **How this relates to GLP-1 care:** Weight-management and diabetes medicines require product-specific review before conception. Do not assume that all GLP-1 products have the same stopping interval or pregnancy guidance. **Safety and when to seek help:** Do not stop essential treatment abruptly; contact the prescriber promptly if pregnancy is planned or suspected while using a medicine not recommended in pregnancy. **Is preconception care only for people with infertility?** No. It can help anyone planning a pregnancy, especially when medicines or chronic conditions are involved. ### Weight-loss percentage Weight-loss percentage expresses change relative to starting weight: the difference between starting and current weight divided by starting weight, multiplied by 100. It is useful for tracking proportional change across people of different sizes but does not show body composition or health by itself. **What this means in India:** Use the same calibrated scale and comparable conditions when reviewing a trend; day-to-day fluid changes can affect weight. **How this relates to GLP-1 care:** Clinicians may use percentage change alongside symptoms, waist, glucose, [lipid profile](/glossary/lipid-profile), function and tolerability when reviewing treatment. **Safety and when to seek help:** Rapid unexplained loss, weakness, dehydration or inability to eat needs clinical review regardless of the percentage. **Does a larger percentage always mean better health?** No. The pace, method, nutrition, muscle preservation and clinical context matter. ### Weight-loss goal A weight-loss goal is an agreed target for change in weight or related health outcomes. Useful goals are individual, realistic and reviewed over time; they may include waist, glucose, mobility, sleep, fitness or quality of life rather than one scale number. **What this means in India:** Goals should account for Indian risk thresholds, food patterns, access, costs, medicines and the person's priorities. **How this relates to GLP-1 care:** A GLP-1 treatment plan should use shared goals to judge benefit and tolerability instead of promising a fixed result. **Safety and when to seek help:** Avoid unsafe deadlines, extreme restriction or independent dose escalation to chase a number. **Must everyone aim for an ideal BMI?** No. Clinically meaningful goals differ and should be agreed with the care team. ### Treatment plateau A treatment plateau is a period when a measured outcome, such as weight or glucose improvement, changes little after earlier progress. Short plateaus can reflect normal biological variation, fluid changes, adherence, measurement conditions or a new balance between intake and energy use. **What this means in India:** Review affordability, access, diet, activity, sleep, medicines and underlying conditions rather than assuming the treatment has failed. **How this relates to GLP-1 care:** A plateau is not automatically non-response. Clinicians may review treatment duration, dose stage, tolerability, goals and other outcomes before deciding what it means. **Safety and when to seek help:** Do not combine products, increase the dose or stop abruptly without the prescriber. **Does a one-week stable weight mean a plateau?** Not necessarily. A meaningful plateau is judged over an appropriate period and in context. ### Incretin effect The incretin effect is the stronger insulin response usually produced by oral glucose than by an equivalent intravenous glucose exposure. Gut hormones including GLP-1 and GIP help create this effect. **What this means in India:** It is a physiology term, not a test that independently determines treatment eligibility. **How this relates to GLP-1 care:** It helps explain why incretin-based medicines target GLP-1, GIP or both pathways. **Safety and when to seek help:** Medicine effects remain product-specific; never combine or switch treatments without a prescriber. **Is the incretin effect the same as a GLP-1 medicine?** No. It is a natural physiological response; a medicine is a specific treatment. ### Brand name A brand name is the commercial name chosen for a medicine by its manufacturer or marketer. It differs from the generic or active-ingredient name. **What this means in India:** The same ingredient may be sold under different brands, and brands can differ in formulation, device or authorised use. **How this relates to GLP-1 care:** Do not assume every product described as a GLP-1 medicine is interchangeable. **Safety and when to seek help:** Verify the active ingredient, strength, indication and authorised source with a clinician or pharmacist. **Is a brand name proof of approval?** No. Check current Indian regulatory and product information. ### Placebo A placebo is an inactive or comparison intervention used in some studies to help researchers estimate a treatment's effect. **What this means in India:** Ethics review and informed consent requirements apply to clinical research in India. **How this relates to GLP-1 care:** Placebo-controlled evidence may inform assessment of a medicine, but it does not predict an individual's result. **Safety and when to seek help:** Never stop prescribed treatment to imitate a study design. **Does a placebo mean participants receive no care?** Not necessarily; study designs and background care vary. ### Class III obesity Class III obesity is a BMI category commonly used for very high BMI. Classification systems and thresholds must be named because population-specific guidance can differ. **What this means in India:** South Asian risk may occur at lower BMI, so one international category should not replace Indian clinical assessment. **How this relates to GLP-1 care:** BMI class alone does not establish eligibility for a particular medicine. **Safety and when to seek help:** Seek individual assessment for weight-related symptoms or conditions; avoid stigmatising labels. **Is Class III obesity a judgment about a person?** No. It is a clinical classification, not a description of character or worth. ### Diabetic neuropathy Diabetic neuropathy is nerve damage associated with diabetes. It may cause numbness, tingling, burning pain, weakness or digestive and other autonomic symptoms. **What this means in India:** Regular foot checks and glucose management are especially important where access to specialist care may vary. **How this relates to GLP-1 care:** Improved glucose control may help reduce risk, but GLP-1 treatment does not directly diagnose or reverse every neuropathy. **Safety and when to seek help:** Urgent care is needed for a new foot wound, spreading infection, sudden weakness or loss of bladder or bowel control. **Can neuropathy occur without pain?** Yes. Numbness can be a major feature. ### eGFR Estimated glomerular filtration rate (eGFR) is a calculated estimate of how well the kidneys filter blood, usually based on creatinine plus personal factors. **What this means in India:** Indian laboratories may report eGFR with creatinine; interpretation should include trends and urine testing when relevant. **How this relates to GLP-1 care:** Kidney function can affect medicine selection and monitoring, while vomiting or dehydration can worsen results. **Safety and when to seek help:** Prompt care is needed for very low urine output, severe dehydration, swelling with breathlessness or confusion. **Is eGFR directly measured?** Usually no. It is estimated from a blood result and other information. ### Energy density Energy density describes the amount of energy, usually calories, in a given weight of food. Foods with more water or fibre often have lower energy density. **What this means in India:** Indian dishes vary greatly by recipe, oil, sugar and water content, so the dish name alone cannot establish energy density. **How this relates to GLP-1 care:** Food quality and adequate nutrition still matter if appetite falls during treatment. **Safety and when to seek help:** Avoid extreme restriction; seek help if intake becomes inadequate or causes weakness. **Is low energy density always healthier?** No. Overall nutrients, portion, preparation and individual needs also matter. ### Eggs Eggs are a protein-rich food that also provides fat and several vitamins and minerals. Their role depends on the whole diet and individual needs. **What this means in India:** They can fit many Indian meal patterns; vegetarian definitions and personal preferences differ. **How this relates to GLP-1 care:** Protein-containing foods may help preserve nutrition when portions are smaller, but no single food makes GLP-1 treatment work. **Safety and when to seek help:** People with allergy or a prescribed medical diet need individual guidance; cook and store eggs safely. **How many eggs should everyone eat?** There is no universal number; needs and health context differ. ### Free sugar Free sugars include sugars added to foods or drinks and sugars naturally present in honey, syrups, fruit juices and juice concentrates. They do not include sugars naturally present inside intact fruit or milk. **What this means in India:** Check packaged-food labels and remember that jaggery, honey and syrups still contribute free sugars. **How this relates to GLP-1 care:** Reducing sugary drinks can support metabolic health, but it does not replace prescribed treatment. **Safety and when to seek help:** Do not manage recurrent low glucose by broadly eliminating all sugar without a clinician's plan. **Is jaggery excluded from free sugar?** No. It is still an added sugar. ### NEAT Non-exercise activity thermogenesis (NEAT) is energy used in everyday movement outside planned exercise, such as standing, walking during tasks and household activity. **What this means in India:** Daily movement varies with work, transport, caregiving, climate and mobility. **How this relates to GLP-1 care:** It can support overall activity but is not a substitute for prescribed exercise or medicine. **Safety and when to seek help:** Increase movement gradually and seek advice for chest pain, faintness or major mobility limitations. **Is NEAT the same as a workout?** No. It refers to ordinary movement outside planned exercise. ### Perioperative fasting Perioperative fasting means instructions about eating and drinking before and around an operation or procedure requiring anaesthesia or sedation. **What this means in India:** Follow the hospital and anaesthesia team's current instructions; policies can vary by procedure and patient risk. **How this relates to GLP-1 care:** GLP-1 medicines can slow stomach emptying, so the team must know the exact product, dose, symptoms and timing. Current guidance often allows continuation for many patients but requires individual risk assessment. **Safety and when to seek help:** Do not independently stop a medicine or ignore fasting instructions. Contact the procedure team if vomiting, marked bloating or severe abdominal symptoms occur. **Should everyone stop GLP-1 medicine before surgery?** No universal answer applies; the anaesthesia and prescribing teams should decide together. ### Waist change Waist change is the difference in waist circumference over time when measurements use the same method. **What this means in India:** Use a consistent tape position and conditions; thresholds and interpretation can vary by guideline. **How this relates to GLP-1 care:** It can complement weight, glucose and other outcomes but does not alone establish treatment success. **Safety and when to seek help:** Rapid abdominal enlargement with pain, swelling or breathlessness needs assessment. **Is a smaller waist always fat loss?** Not necessarily; technique, bloating and fluid changes can affect the measurement. ### Informed consent Informed consent is a voluntary decision made after receiving understandable information about purpose, expected benefits, risks, alternatives and the right to ask questions or decline. **What this means in India:** Indian clinical research follows ethics and regulatory requirements; routine treatment also requires meaningful discussion and patient choice. **How this relates to GLP-1 care:** Consent for a GLP-1 medicine should cover product-specific benefits, risks, alternatives and monitoring. **Safety and when to seek help:** A signature alone is not enough if information was unclear or pressure was applied. **Can consent be withdrawn?** In research, participants generally retain the right to withdraw according to the applicable process; treatment choices can also be revisited with the clinician. ### Glycaemic goal A glycaemic goal is an agreed target for glucose measures such as HbA1c, fasting glucose or time in range. Goals are individual rather than universal. **What this means in India:** The clinician may consider age, pregnancy, other illnesses, hypoglycaemia risk, medicines and access to monitoring. **How this relates to GLP-1 care:** GLP-1 therapy may be one part of a plan, but the goal does not determine the medicine by itself. **Safety and when to seek help:** Repeated low readings, severe symptoms or a sudden deterioration need prompt review rather than self-adjustment. **Is a lower HbA1c always better?** Not if reaching it causes harmful hypoglycaemia or other treatment burden. ### Reproductive age Reproductive age is a population-health term for ages during which pregnancy may occur; exact age ranges vary by source and purpose. Age alone does not establish fertility or pregnancy status. **What this means in India:** Use respectful, individual history rather than assumptions about marriage, fertility or pregnancy intentions. **How this relates to GLP-1 care:** Pregnancy planning, pregnancy and breastfeeding can materially change whether a medicine is appropriate. **Safety and when to seek help:** Discuss contraception, pregnancy plans or a possible pregnancy promptly with the prescriber; do not stop treatment without advice unless urgent care directs it. **Does reproductive age mean someone can become pregnant?** No. It is a broad statistical term, not an individual diagnosis. ### Gut hormone A gut hormone is a chemical messenger released by cells in the digestive system. Examples include GLP-1, GIP, ghrelin and cholecystokinin. **What this means in India:** The term describes biology, not a medicine approval or diagnosis. **How this relates to GLP-1 care:** Some treatments imitate or modify particular gut-hormone pathways. **Safety and when to seek help:** Effects are hormone- and product-specific; do not treat all ‘gut hormone’ products as equivalent. **Are all gut hormones appetite hormones?** No. They have varied roles in digestion, glucose control and other functions. ### Dose A dose is the measured amount of a medicine taken at one time or according to a defined schedule. **What this means in India:** Use the exact Indian product label and prescription; different strengths and devices are not interchangeable. **How this relates to GLP-1 care:** Starting, escalation and maintenance schedules vary by molecule, indication and patient. **Safety and when to seek help:** Never copy another person's dose or change it without the prescriber. **Is a higher dose always more effective?** No. Benefits and adverse effects are dose- and person-dependent. ### Randomised controlled trial A randomised controlled trial assigns participants by chance to intervention groups so outcomes can be compared with less selection bias. **What this means in India:** Indian trials require applicable regulatory and ethics oversight; trial permission is not marketing approval. **How this relates to GLP-1 care:** Trials help estimate benefits and risks but do not predict one person's response. **Safety and when to seek help:** Do not change treatment merely to match a study protocol. **Does randomisation guarantee a perfect study?** No. Study size, duration, dropouts, outcomes and relevance still matter. ### Subcutaneous fat Subcutaneous fat is fat stored beneath the skin. It differs from visceral fat stored around internal abdominal organs. **What this means in India:** Body-fat distribution and risk should be interpreted with Indian or South Asian context. **How this relates to GLP-1 care:** Weight change can affect both compartments, but a scale cannot reliably separate them. **Safety and when to seek help:** Consumer estimates are not a diagnosis; sudden swelling or painful lumps need assessment. **Is subcutaneous fat harmless?** Not necessarily; overall amount, distribution and health context matter. ### Type 1 diabetes Type 1 diabetes is an autoimmune condition in which the pancreas makes little or no insulin. Daily insulin is essential for survival. **What this means in India:** Diagnosis and ongoing care require a qualified diabetes team and access to insulin and monitoring. **How this relates to GLP-1 care:** GLP-1 medicines do not replace insulin and product indications must be checked carefully. **Safety and when to seek help:** High glucose with ketones, vomiting, deep breathing or confusion is an emergency. **Can type 1 diabetes be treated without insulin?** No. Insulin is essential. ### Diabetic nephropathy Diabetic nephropathy is kidney damage associated with diabetes, often assessed using eGFR and urine albumin-to-creatinine ratio. **What this means in India:** Regular kidney checks matter because early disease may have no symptoms. **How this relates to GLP-1 care:** Glucose and blood-pressure management can affect kidney risk; medicine selection remains individual. **Safety and when to seek help:** Very low urine output, severe swelling, breathlessness or confusion needs prompt care. **Is one high creatinine enough to diagnose it?** No. Trends, urine testing and clinical assessment are needed. ### Chronic inflammation Chronic inflammation is a prolonged immune response that can accompany infections, autoimmune disease, obesity and other conditions. **What this means in India:** It is a broad biological term, not a diagnosis based on one symptom or commercial test. **How this relates to GLP-1 care:** Metabolic improvement may influence inflammatory markers, but GLP-1 treatment is not a universal anti-inflammatory therapy. **Safety and when to seek help:** Persistent fever, unexplained weight loss or significant symptoms need clinical review. **Does one raised CRP identify the cause?** No. It is non-specific and must be interpreted in context. ### Appetite suppression Appetite suppression means a reduced desire to eat. It can result from medicines, illness, stress or other factors. **What this means in India:** Reduced appetite must still allow adequate nutrition and fluids using culturally and financially practical foods. **How this relates to GLP-1 care:** It can occur with GLP-1 treatment, but complete inability to eat is not the goal. **Safety and when to seek help:** Persistent vomiting, weakness, dehydration or rapid unintended loss needs review. **Is less appetite always beneficial?** No. Excessive reduction can impair nutrition and treatment tolerance. ### Millets Millets are a group of cereal grains such as ragi, jowar and bajra. They provide carbohydrate plus varying amounts of fibre, protein and micronutrients. **What this means in India:** ICMR-NIN includes millets within diverse cereal choices; preparation and portion affect the meal. **How this relates to GLP-1 care:** They can fit a balanced diet but do not independently produce weight loss or glucose control. **Safety and when to seek help:** People with allergies or prescribed dietary restrictions need individual advice. **Are millets carbohydrate-free?** No. They are cereal grains and contain carbohydrate. ### Fat Dietary fat is a nutrient that provides energy, supports cell function and helps absorb fat-soluble vitamins. Types include unsaturated and saturated fats. **What this means in India:** Cooking oils, ghee, nuts, seeds, dairy and packaged foods contribute different fats; portions and the whole diet matter. **How this relates to GLP-1 care:** Fat is not inherently incompatible with GLP-1 care, although very rich meals may worsen digestive symptoms for some people. **Safety and when to seek help:** Seek individual guidance for gallbladder, pancreatic or lipid disorders. **Should all fat be removed for weight loss?** No. Type, amount, nutritional adequacy and total diet matter. ### Sedentary behaviour Sedentary behaviour is waking time spent sitting, reclining or lying with very low energy expenditure. It is different from simply not completing a workout. **What this means in India:** Desk work, study, transport and screen time can contribute; practical breaks depend on mobility and environment. **How this relates to GLP-1 care:** Reducing long sitting periods complements nutrition and prescribed activity. **Safety and when to seek help:** Increase activity gradually and seek advice for chest pain, faintness or major limitations. **Can someone exercise and still be sedentary?** Yes. A person may exercise yet sit for much of the remaining day. ### Bloating Bloating is a feeling of abdominal fullness, pressure or swelling, sometimes with visible distension. **What this means in India:** Food patterns, constipation, digestive illness and medicines are possible contributors. **How this relates to GLP-1 care:** Bloating can occur during GLP-1 treatment, but severe or persistent symptoms need assessment. **Safety and when to seek help:** Urgent care is needed for severe pain, repeated vomiting, inability to pass stool or gas, faintness or breathing difficulty. **Is bloating always caused by gas?** No. Several digestive and non-digestive conditions can cause it. ### Adverse event An adverse event is an unwanted medical occurrence during treatment or research, whether or not the medicine caused it. **What this means in India:** Serious reactions and suspected quality problems can be reported through healthcare and official pharmacovigilance channels. **How this relates to GLP-1 care:** Timing alone does not prove causation, but symptoms should be documented and assessed. **Safety and when to seek help:** Emergency symptoms need immediate care rather than waiting to file a report. **Is every adverse event a side effect?** No. A side effect implies a recognised relationship; an adverse event may be unrelated. ### Blood glucose log A blood glucose log records readings with dates, times and useful context such as meals, activity, symptoms and medicine timing. **What this means in India:** Units and device type should be recorded; Indian meters commonly use mg/dL. **How this relates to GLP-1 care:** Patterns can support a monitoring visit, but the log should not drive unsupervised dose changes. **Safety and when to seek help:** Severe low- or high-glucose symptoms require the person's emergency plan. **Should every reading be judged alone?** No. Patterns, symptoms and clinical targets are more informative. ### Shared decision-making Shared decision-making is a conversation in which clinician expertise and the patient's goals, preferences and circumstances inform a healthcare choice. **What this means in India:** Cost, access, language, food practices, family support and follow-up feasibility may be relevant. **How this relates to GLP-1 care:** Treatment choices should cover expected benefits, risks, alternatives and monitoring. **Safety and when to seek help:** It does not remove the need for informed consent or professional responsibility. **Does it mean the clinician simply agrees to any request?** No. The decision stays within safe, evidence-based options. ### Monitoring visit A monitoring visit is a follow-up appointment used to review response, symptoms, adherence, measurements, tests and the ongoing treatment plan. **What this means in India:** It may occur in person or remotely where appropriate, but urgent symptoms need timely care. **How this relates to GLP-1 care:** GLP-1 follow-up can include tolerance, nutrition, glucose risk and product-specific checks. **Safety and when to seek help:** Do not wait for a routine visit when red-flag symptoms occur. **Is monitoring only about body weight?** No. Safety, symptoms, nutrition, glucose and other health measures can matter. ### Acanthosis nigricans Acanthosis nigricans describes darkened, thickened, velvety skin, often on the neck, armpits or groin. It can be associated with insulin resistance but has other causes. **What this means in India:** Clinical assessment is needed; appearance alone does not diagnose diabetes or PCOS. **How this relates to GLP-1 care:** Treating an underlying metabolic condition may help, but GLP-1 eligibility cannot be inferred from the skin finding. **Safety and when to seek help:** Rapid onset, extensive changes or involvement with other symptoms needs medical review. **Is it caused by poor hygiene?** No. Scrubbing does not address the underlying cause and can irritate skin. ### Pancreatic beta cell A pancreatic beta cell is an insulin-producing cell in the islets of the pancreas. **What this means in India:** The biological term does not describe a medicine approval or a person's remaining insulin capacity. **How this relates to GLP-1 care:** GLP-1 signalling can stimulate glucose-dependent insulin release from functioning beta cells. **Safety and when to seek help:** Type 1 diabetes destroys beta cells; GLP-1 treatment does not replace essential insulin. **Can a routine test count beta cells?** No. Ordinary diabetes tests assess glucose control or insulin-related function indirectly. ### Starting dose A starting dose is the amount used when beginning a medicine. It may be selected to improve tolerability rather than provide the full intended treatment effect. **What this means in India:** Use only the exact Indian product label and prescription. **How this relates to GLP-1 care:** Starting doses and schedules vary by molecule, formulation and indication. **Safety and when to seek help:** Never copy another person's dose or accelerate the schedule yourself. **Is the starting dose always the long-term dose?** No. Some products use planned escalation, while others do not. ### Real-world evidence Real-world evidence is clinical evidence developed from data collected outside traditional randomised trials, such as health records, registries or routine care. **What this means in India:** Data quality, population and regulatory purpose must be stated; an overseas study may not represent Indian practice. **How this relates to GLP-1 care:** It can complement trials but cannot predict one person's response or expand a product's approval. **Safety and when to seek help:** Do not treat an observational association as proof of cause. **Is real-world evidence the same as a clinical trial?** No. Designs, controls and sources of bias differ. ### Body fat percentage Body fat percentage estimates the share of total body mass made up of fat. **What this means in India:** Devices and equations vary, and hydration can affect some estimates. **How this relates to GLP-1 care:** It may add context to weight change but is not a treatment target for everyone. **Safety and when to seek help:** Consumer-device readings are not a diagnosis; focus on consistent methods and wider health measures. **Is body fat percentage the same as visceral fat?** No. It does not show where fat is stored. ### Gestational diabetes Gestational diabetes is diabetes first diagnosed during pregnancy in someone who did not have known diabetes beforehand. **What this means in India:** Screening and diagnostic protocols should follow the obstetric team's Indian pathway. **How this relates to GLP-1 care:** Pregnancy treatment decisions are distinct from routine GLP-1 weight-management care. **Safety and when to seek help:** High glucose in pregnancy needs timely clinical management; do not self-treat. **Does it always disappear after delivery?** Glucose may normalise, but future type 2 diabetes risk remains higher and follow-up testing matters. ### Diabetic retinopathy Diabetic retinopathy is damage to retinal blood vessels associated with diabetes. **What this means in India:** Regular dilated eye assessment may be recommended even before symptoms appear. **How this relates to GLP-1 care:** Rapid glucose improvement can require eye context and monitoring in some patients. **Safety and when to seek help:** Sudden vision loss, many new floaters or a curtain-like shadow needs urgent eye care. **Can a normal vision check replace retinal examination?** No. Early retinopathy may not affect day-to-day vision. ### Hyperuricaemia Hyperuricaemia means a higher-than-reference concentration of uric acid in the blood. **What this means in India:** Laboratory ranges and clinical context matter; one result does not diagnose gout. **How this relates to GLP-1 care:** Weight, kidney function, medicines and hydration may affect uric acid, but GLP-1 treatment is not a specific gout therapy. **Safety and when to seek help:** A hot, swollen joint, fever or kidney-stone symptoms need assessment. **Does high uric acid always cause symptoms?** No. Many people have no symptoms. ### Cholecystokinin (CCK) Cholecystokinin is a gut hormone released after eating that helps coordinate digestion and contributes to meal-ending signals. **What this means in India:** It is a physiological term, not an approved weight-loss product claim. **How this relates to GLP-1 care:** CCK and GLP-1 are different hormones with overlapping digestive and appetite-related effects. **Safety and when to seek help:** Commercial products claiming to manipulate CCK should not replace medical or nutrition advice. **Is CCK the same as GLP-1?** No. They are different hormones and receptors. ### Roti Roti is a broad term for Indian flatbread, often made from whole-wheat atta but also from millet or other flours. **What this means in India:** Ingredients, size, added fat and preparation vary widely. **How this relates to GLP-1 care:** Roti can fit a balanced plate; it is not carbohydrate-free and portion tolerance may change during treatment. **Safety and when to seek help:** People with coeliac disease or wheat allergy need appropriate alternatives. **Is roti always whole grain?** No. Check the flour and preparation. ### Saturated fat Saturated fat is a type of dietary fat found in varying amounts in ghee, butter, high-fat dairy, meat, coconut, palm oil and many packaged foods. **What this means in India:** ICMR-NIN advises attention to fat quality and overall dietary pattern. **How this relates to GLP-1 care:** Very rich meals may worsen digestive symptoms for some people, but GLP-1 care does not require eliminating all fat. **Safety and when to seek help:** Discuss individual targets for high LDL cholesterol, gallbladder or pancreatic disease. **Is every plant oil low in saturated fat?** No. Coconut and palm oils are relatively high. ### Progressive overload Progressive overload is the gradual increase of training demand as the body adapts, such as more repetitions, resistance, range or control. **What this means in India:** The progression should match equipment, supervision and individual ability. **How this relates to GLP-1 care:** Appropriate resistance training may support muscle during weight loss. **Safety and when to seek help:** Stop and seek advice for chest pain, fainting, severe breathlessness or injury; increase gradually. **Does it mean adding weight every workout?** No. Progress can use several variables and should include recovery. ### Indigestion Indigestion is upper-abdominal discomfort that may include burning, early fullness, post-meal fullness, nausea or belching. **What this means in India:** The word describes symptoms rather than one diagnosis. **How this relates to GLP-1 care:** Digestive symptoms can occur during GLP-1 treatment, but persistent symptoms should be assessed. **Safety and when to seek help:** Urgent care is needed for severe pain, blood in vomit or stool, fainting, breathing difficulty or repeated vomiting. **Is indigestion the same as acid reflux?** No. They can overlap but are distinct symptom patterns. ### Serious adverse event A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalisation, causes significant disability, causes a birth defect, or is medically important under applicable reporting rules. **What this means in India:** Seriousness is a regulatory category and is not the same as symptom intensity. **How this relates to GLP-1 care:** A serious event during treatment does not automatically prove the medicine caused it, but it requires assessment and reporting. **Safety and when to seek help:** Emergency care comes before completing a safety report. **Is every severe symptom a serious adverse event?** Not necessarily; severity and regulatory seriousness describe different concepts. ### Side-effect diary A side-effect diary records symptoms with date, timing, severity, food and fluid intake, bowel pattern, medicine timing and actions taken. **What this means in India:** Use plain language and bring it to the treating team; it is not a substitute for urgent care. **How this relates to GLP-1 care:** Patterns can support a safer treatment review and distinguish transient from continuing problems. **Safety and when to seek help:** Red-flag symptoms need immediate assessment rather than waiting to record more entries. **Should the diary include only digestive symptoms?** No. Record any relevant symptom and context without assuming causation. ### Prescription A prescription is a clinician's authorised instruction for a specific medicine, patient, strength, route and schedule. **What this means in India:** Prescription-only GLP-1 medicines should come through lawful Indian clinical and pharmacy channels. **How this relates to GLP-1 care:** A prescription follows assessment and does not make monitoring optional. **Safety and when to seek help:** Do not share prescriptions, pens or tablets or reuse an old prescription without review. **Does a prescription guarantee suitability forever?** No. Health, medicines and treatment response can change. ### Irregular periods Irregular periods are menstrual cycles that vary substantially in timing, frequency, duration or flow. **What this means in India:** Pregnancy, PCOS, thyroid conditions, stress, nutrition and other causes should be considered. **How this relates to GLP-1 care:** Weight or metabolic treatment may coincide with cycle changes but does not identify the cause. **Safety and when to seek help:** Seek care for possible pregnancy, very heavy bleeding, severe pain, fainting or prolonged absence of periods. **Does an irregular cycle prove PCOS?** No. PCOS requires broader assessment. ### Amenorrhoea Amenorrhoea means the absence of menstrual periods, either because they never began by the expected age or because previously occurring periods stopped. **What this means in India:** Pregnancy must be considered where relevant, along with PCOS, thyroid, nutrition, stress and other causes. **How this relates to GLP-1 care:** It is not a desired marker of successful weight loss or GLP-1 response. **Safety and when to seek help:** Prompt review is needed with possible pregnancy, severe pain, neurological symptoms or prolonged absence. **Can rapid weight loss affect periods?** Yes, but other causes must still be assessed. ### Insulin secretion Insulin secretion is the release of insulin from pancreatic beta cells, especially when blood glucose rises. **What this means in India:** It is a biological process, not the same as injected insulin or an approval claim. **How this relates to GLP-1 care:** GLP-1 medicines enhance insulin release in a glucose-dependent manner. **Safety and when to seek help:** Low-glucose risk can still increase when treatment is combined with insulin or certain medicines. **Does more insulin secretion always mean better health?** No. The amount and timing must match the body's needs. ### Maintenance dose A maintenance dose is the dose intended to continue after any starting or escalation period. **What this means in India:** The authorised options depend on the exact Indian product and indication. **How this relates to GLP-1 care:** Not everyone reaches the same maintenance dose, and tolerability and response matter. **Safety and when to seek help:** Do not increase, reduce or restart at a maintenance dose without the prescriber. **Is the highest dose always the maintenance dose?** No. Product instructions and individual care determine it. ### Adipose tissue Adipose tissue is body tissue made largely of fat-storing cells called adipocytes. It also has hormonal and metabolic functions. **What this means in India:** Distribution and metabolic risk vary; one body measurement cannot characterise all adipose tissue. **How this relates to GLP-1 care:** Weight change can affect adipose tissue, but a scale does not show exact tissue compartments. **Safety and when to seek help:** Painful lumps, sudden swelling or rapid unexplained change needs assessment. **Is adipose tissue simply inactive storage?** No. It is metabolically active tissue. ### Insulin sensitivity Insulin sensitivity describes how effectively body tissues respond to insulin. **What this means in India:** It is inferred from clinical and laboratory context rather than one routine direct test. **How this relates to GLP-1 care:** Weight, activity, sleep, illness and medicines may influence sensitivity; GLP-1 treatment has several mechanisms. **Safety and when to seek help:** Do not change diabetes medicine based on a consumer estimate of insulin sensitivity. **Is insulin sensitivity the opposite of insulin resistance?** They describe opposite ends of the same response concept. ### Albuminuria Albuminuria means albumin is present in urine above the expected amount and can be a sign of kidney damage. **What this means in India:** Urine albumin-to-creatinine ratio is commonly used, and abnormal results may need confirmation. **How this relates to GLP-1 care:** It adds kidney-risk context but is not a direct measure of GLP-1 response. **Safety and when to seek help:** Very low urine output, severe swelling or breathlessness needs prompt care. **Can exercise or infection affect a result?** Yes. Temporary factors can influence urine albumin, so context and repeat testing may matter. ### Uric acid Uric acid is a waste product formed when the body breaks down purines and is removed mainly by the kidneys. **What this means in India:** A blood level must be interpreted with symptoms, kidney function and the laboratory range. **How this relates to GLP-1 care:** Hydration, weight change and medicines can affect it, but it is not a routine GLP-1 success measure. **Safety and when to seek help:** Sudden painful joint swelling or severe side or back pain needs assessment. **Is uric acid the same as gout?** No. Gout is an inflammatory arthritis related to urate crystals. ### Peptide YY (PYY) Peptide YY is a gut hormone released after eating that participates in digestive and appetite signalling. **What this means in India:** It is a biological term, not a consumer test or approved product category. **How this relates to GLP-1 care:** PYY and GLP-1 are distinct hormones that may both contribute to post-meal responses. **Safety and when to seek help:** Avoid products making unsupported claims to control PYY. **Can PYY levels diagnose appetite problems?** No. It is not a routine standalone diagnostic test. ### Chapati Chapati is an unleavened flatbread commonly made from atta. Usage overlaps with roti, although regional meanings and preparation vary. **What this means in India:** Size, flour and added fat affect nutrition and glucose impact. **How this relates to GLP-1 care:** Chapati can fit a balanced plate in a tolerable portion during GLP-1 treatment. **Safety and when to seek help:** Use gluten-free alternatives for coeliac disease or wheat allergy as clinically appropriate. **Is chapati carbohydrate-free?** No. Flour-based chapati contains carbohydrate. ### Unsaturated fat Unsaturated fats include monounsaturated and polyunsaturated fats found in varying amounts in nuts, seeds, fish and many plant oils. **What this means in India:** Oil type, quantity, cooking method and the whole diet matter. **How this relates to GLP-1 care:** They can be part of balanced GLP-1 nutrition; energy density and digestive tolerance still matter. **Safety and when to seek help:** Individual advice may be needed for lipid, gallbladder or pancreatic disease. **Does unsaturated mean unlimited?** No. Fats are energy-dense and portions matter. ### Protein timing Protein timing describes when protein-containing foods are eaten across the day or around activity. **What this means in India:** Regular access to familiar protein foods matters more than rigid imported schedules for most people. **How this relates to GLP-1 care:** Distributing tolerable protein intake may help when appetite is reduced, but total adequacy and resistance activity remain important. **Safety and when to seek help:** People with kidney or liver disease need individual advice before changing intake. **Is there one perfect time to eat protein?** No. Goals, total intake, training and tolerance differ. ### Dyspepsia Dyspepsia is a medical term for recurring upper-abdominal symptoms such as pain, burning, early fullness or uncomfortable post-meal fullness. **What this means in India:** It is a symptom syndrome with several possible causes. **How this relates to GLP-1 care:** It may overlap with treatment-related digestive effects but should not be assumed to be caused by GLP-1 medicine. **Safety and when to seek help:** Seek urgent care for bleeding, severe pain, fainting, breathing difficulty or persistent vomiting. **Is dyspepsia the same as GERD?** No. They can overlap, but GERD concerns reflux of stomach contents. ### Weight Weight is total body mass measured on a scale and includes fat, muscle, bone, organs and water. **What this means in India:** Use the same reliable scale and similar conditions for useful trends. **How this relates to GLP-1 care:** Weight is one treatment outcome and should be considered with health, nutrition, strength and symptoms. **Safety and when to seek help:** Rapid change with swelling, dehydration, severe weakness or illness needs review. **Does a daily change represent fat change?** Usually not; fluid and digestive contents can shift quickly. ### Medication review A medication review is a structured check of all prescription, non-prescription, supplement and traditional products for purpose, dose, benefit, risk and interactions. **What this means in India:** Bring names, strengths, schedules and packaging where possible. **How this relates to GLP-1 care:** Review matters before starting or changing GLP-1 treatment and when symptoms or glucose patterns change. **Safety and when to seek help:** Do not stop essential medicines while waiting for a routine review. **Should supplements be included?** Yes. Include vitamins, herbal products and over-the-counter medicines. ### Screening Screening tests people without recognised symptoms to identify higher risk or possible disease that needs further assessment. **What this means in India:** The appropriate programme, age and test depend on Indian guidance and individual risk. **How this relates to GLP-1 care:** Screening can inform care but does not itself establish GLP-1 eligibility. **Safety and when to seek help:** A positive screen is not a final diagnosis; a negative screen does not rule out every condition. **Is screening the same as diagnosis?** No. Abnormal screening results usually require confirmation. ### Ovulation Ovulation is the release of an egg from an ovary during the menstrual cycle. **What this means in India:** Cycle timing varies, especially with PCOS, illness, stress, pregnancy-related changes and changing weight. **How this relates to GLP-1 care:** Metabolic treatment may coincide with fertility changes, so contraception and pregnancy planning matter. **Safety and when to seek help:** Discuss missed periods or possible pregnancy promptly; do not use cycle apps alone as contraception. **Does a regular period prove ovulation?** Not always. ### Androgen excess Androgen excess means higher androgen activity or levels and can contribute to acne, excess facial or body hair, scalp hair thinning and irregular cycles. **What this means in India:** PCOS is a common cause, but medicines and adrenal or ovarian conditions may also be considered. **How this relates to GLP-1 care:** Weight or insulin-related care may be part of management but does not replace diagnosis. **Safety and when to seek help:** Rapid virilisation, voice change or severe symptoms needs prompt specialist assessment. **Does one symptom prove androgen excess?** No. History, examination and selected tests are used. ### Prescription-only medicine A prescription-only medicine requires an authorised prescription and professional oversight rather than unrestricted self-purchase. **What this means in India:** Government of India surveillance has targeted unauthorised GLP-1 sale and promotion. **How this relates to GLP-1 care:** GLP-1 and dual-agonist treatment requires product-specific assessment, dosing and monitoring. **Safety and when to seek help:** Avoid on-demand sellers, shared devices and products without traceable supply. **Does pharmacy availability remove the need for a prescription?** No. ### Glucagon suppression Glucagon suppression means reducing glucagon release when glucose is elevated. Glucagon is a pancreatic hormone that helps raise blood glucose, partly by signalling the liver. **What this means in India:** It is a mechanism term, not a routine home test or a reason to change medicine. **How this relates to GLP-1 care:** GLP-1 signalling can reduce glucagon when glucose is elevated, alongside supporting glucose-dependent insulin secretion. **Safety and when to seek help:** Severe or recurrent low-glucose symptoms require prompt review, especially with insulin or sulfonylureas. **Does glucagon always need to be suppressed?** No. Glucagon has normal roles, including protection when glucose falls. ### Once-weekly injection A once-weekly injection is given on one scheduled day each week. Different medicines, pens, strengths and missed-dose rules are not interchangeable. **What this means in India:** Use only a CDSCO-authorised product supplied against a valid prescription and follow its Indian instructions. **How this relates to GLP-1 care:** Some GLP-1 or dual-agonist products use weekly dosing because their effects persist for several days. **Safety and when to seek help:** Never repeat a dose after uncertainty, share a device or improvise a missed-dose plan. Contact the prescriber or pharmacist. **Can I move the injection day?** Only according to the exact product instructions and clinician's plan. ### Waist-to-hip ratio Waist-to-hip ratio divides waist circumference by hip circumference. It is a screening measure of body-fat distribution, not a direct scan of visceral fat. **What this means in India:** Technique and population context matter. Indian waist thresholds may be more familiar in routine metabolic assessment. **How this relates to GLP-1 care:** It can add risk context but does not determine GLP-1 eligibility or response. **Safety and when to seek help:** Sudden abdominal swelling, pain or major unexplained change needs assessment rather than repeated measuring. **Is a lower ratio always healthier?** Not necessarily. Age, sex, body build and the measurement method affect interpretation. ### Hyperglycaemia Hyperglycaemia means blood glucose is above the appropriate target or diagnostic range for the situation. Symptoms can include thirst, frequent urination, tiredness and blurred vision, but it may be silent. **What this means in India:** Use the units, timing and clinician-set targets on the Indian laboratory or monitoring plan. **How this relates to GLP-1 care:** GLP-1 medicines may lower glucose, but treatment decisions use the full diabetes plan. **Safety and when to seek help:** Urgent assessment is needed for marked hyperglycaemia with vomiting, abdominal pain, deep breathing, confusion, dehydration or ketones. **Does one high home reading diagnose diabetes?** No. Diagnosis requires an appropriate laboratory test and clinical interpretation. ### Estimated average glucose Estimated average glucose (eAG) converts an HbA1c result into an approximate average glucose value using a mathematical relationship. It is not the arithmetic mean of a few meter readings. **What this means in India:** Check whether the report uses mg/dL or mmol/L and interpret it with HbA1c limitations. **How this relates to GLP-1 care:** It can summarise longer-term glucose context but does not show daily peaks, lows or treatment tolerance. **Safety and when to seek help:** Unexpected disagreement between HbA1c, eAG and symptoms may need review for anaemia, haemoglobin variants, kidney disease or other factors. **Can eAG replace glucose monitoring?** No. It does not show timing or variability. ### Gout Gout is an inflammatory arthritis caused by urate crystals, often producing sudden severe pain, redness and swelling in one joint. A high uric-acid level raises risk but does not by itself diagnose gout. **What this means in India:** Diagnosis and medicine choice should account for kidney function, other medicines and Indian clinical access. **How this relates to GLP-1 care:** Weight change and hydration can affect gout context, but GLP-1 treatment is not an acute gout treatment. **Safety and when to seek help:** A hot swollen joint with fever, severe illness or diagnostic uncertainty needs urgent assessment to exclude infection. **Is gout caused only by food?** No. Genetics, kidney handling, medicines and health conditions also contribute. ### Amylin Amylin is a hormone released with insulin by pancreatic beta cells. It participates in post-meal glucose control, gastric emptying and satiety signalling. **What this means in India:** Amylin is a physiology term and is not usually measured in routine care. **How this relates to GLP-1 care:** It acts through pathways distinct from GLP-1, although both can influence post-meal responses. **Safety and when to seek help:** Do not use products making unsupported claims to raise or reset amylin. **Is amylin the same hormone as insulin?** No. They are different hormones that are released together by beta cells. ### Rice Rice is a cereal grain and a major carbohydrate food in many Indian meals. Variety, processing, cooking, portion and the rest of the meal affect nutrition and glucose response. **What this means in India:** Rice can fit a balanced diet alongside pulses, vegetables and an appropriate protein source. **How this relates to GLP-1 care:** During GLP-1 treatment, smaller tolerable portions may help when fullness or nausea is present. **Safety and when to seek help:** People using glucose-lowering medicine should follow their personal plan rather than abruptly removing staple carbohydrate. **Must rice be completely avoided for weight loss?** No. Portion, meal pattern and overall diet matter. ### Omega-3 fatty acids Omega-3 fatty acids are a family of polyunsaturated fats. ALA occurs in some seeds and plant oils; EPA and DHA occur mainly in fish and seafood. **What this means in India:** Food choices should fit preference, affordability, allergy and local food-safety advice. **How this relates to GLP-1 care:** Omega-3 foods can be part of balanced nutrition but are not a substitute for GLP-1 medicine or cardiovascular treatment. **Safety and when to seek help:** High-dose supplements can interact with medicines or increase bleeding concerns and need professional review. **Are plant and fish omega-3 identical?** No. They contain different forms, and conversion of ALA to EPA and DHA is limited. ### Recovery Recovery is the process of adapting after physical activity, including rest, sleep, nutrition and time for tissues to repair. It does not mean avoiding all movement. **What this means in India:** A practical recovery plan should match work, sleep, food access and exercise experience. **How this relates to GLP-1 care:** Reduced intake or fatigue during GLP-1 treatment may require adjusting training load and nutrition. **Safety and when to seek help:** Persistent severe pain, swelling, weakness, dark urine, chest symptoms or fainting needs medical assessment. **Does soreness prove a workout was effective?** No. Progress does not require severe soreness. ### Burping Burping is release of swallowed gas from the stomach through the mouth. It can increase with fast eating, fizzy drinks, reflux or delayed digestion. **What this means in India:** Food pattern, meal size and medicine timing can help a clinician assess the cause. **How this relates to GLP-1 care:** Digestive changes during GLP-1 treatment may contribute, but persistent burping should not automatically be attributed to medicine. **Safety and when to seek help:** Seek care for severe pain, repeated vomiting, blood, black stool, breathing difficulty or inability to keep fluids down. **Are all burps caused by acid reflux?** No. Swallowed air and several digestive conditions can contribute. ### Height Height is the measured vertical length of the body. Adult height is used with weight to calculate BMI; in children it must be interpreted using age- and sex-specific growth standards. **What this means in India:** Use a calibrated stadiometer where possible, without shoes and with consistent technique. **How this relates to GLP-1 care:** Height helps calculate BMI but does not measure body fat or GLP-1 response. **Safety and when to seek help:** Unexpected height loss, back pain or fracture risk needs clinical assessment. **Does adult height change day to day?** Small measurement differences can occur from technique and spinal compression. ### GGT Gamma-glutamyl transferase (GGT) is an enzyme measured in blood. It may rise with liver or bile-duct conditions, alcohol exposure and some medicines, but is not specific to one diagnosis. **What this means in India:** Interpret the value using the laboratory range and other liver tests such as ALT, AST and bilirubin. **How this relates to GLP-1 care:** GGT may add metabolic and liver context but is not a routine measure of GLP-1 effectiveness. **Safety and when to seek help:** Jaundice, severe upper-abdominal pain, confusion, dark urine or pale stools needs prompt assessment. **Does a high GGT prove fatty liver?** No. Several causes are possible and further evaluation may be needed. ### Diagnosis A diagnosis is a clinician's identification of a disease or condition using history, examination and appropriate tests. It is different from screening, which identifies possible risk or disease. **What this means in India:** The diagnostic pathway should use applicable Indian standards and authorised professionals. **How this relates to GLP-1 care:** A diagnosis may inform whether GLP-1 treatment is considered, but an online definition cannot establish eligibility. **Safety and when to seek help:** New severe symptoms require timely assessment rather than self-diagnosis. **Can one abnormal test establish a diagnosis?** Sometimes, but many conditions require confirmation and clinical context. ### Contraception Contraception includes methods used to prevent pregnancy. Options differ in effectiveness, duration, interactions, side effects and suitability. **What this means in India:** Access a qualified clinician for a method that fits health history, preferences and Indian availability. **How this relates to GLP-1 care:** Pregnancy planning matters during GLP-1 care because weight-management GLP-1 treatment is not recommended during pregnancy. **Safety and when to seek help:** Suspected pregnancy, severe pelvic pain, heavy bleeding, chest pain or neurological symptoms needs prompt care. **Does weight loss guarantee contraception will work differently?** No. Method-specific evidence and current prescribing information are needed. ### Hirsutism Hirsutism means coarse terminal hair growth in a pattern associated with androgen activity, such as the face, chest or abdomen. It can occur with PCOS but has other causes. **What this means in India:** Assessment may include menstrual history, medicines, examination and selected hormone tests. **How this relates to GLP-1 care:** Metabolic care can be relevant in PCOS, but GLP-1 treatment is not a direct diagnosis or stand-alone treatment for hirsutism. **Safety and when to seek help:** Rapid onset, voice deepening, major muscle change or other virilisation needs prompt specialist assessment. **Does facial hair always mean PCOS?** No. Genetics, medicines and other hormonal conditions can contribute. ### Liraglutide in India Liraglutide is a prescription GLP-1 receptor agonist supplied in product-specific injectable formulations and indications. It should not be assumed to match semaglutide or tirzepatide dosing. **What this means in India:** Verify the exact current CDSCO approval, Indian label, manufacturer, strength and authorised supply channel. **How this relates to GLP-1 care:** Some liraglutide products use daily dosing. Eligibility and dose escalation are product-specific. **Safety and when to seek help:** Do not buy without a prescription, share pens or transfer a dose from another GLP-1 medicine. **Is every liraglutide product approved for weight management?** No. Indications can differ by product and must be checked. ### Appetite regulation Appetite regulation is the interaction of brain, gut, hormones, senses, habits and environment that influences desire to eat. It is not controlled by one hormone or a simple willpower switch. **What this means in India:** Meal patterns, culture, sleep, stress and food access shape appetite in everyday Indian settings. **How this relates to GLP-1 care:** GLP-1 signalling can reduce appetite and increase satiety, but individual experience varies. **Safety and when to seek help:** Complete inability to eat, persistent vomiting, dehydration or rapid weakness needs prompt review. **Is appetite the same as hunger?** No. Hunger includes physical need signals, while appetite also includes desire and cues. ### Daily injection A daily injection is administered once each day according to the exact product instructions. Different devices, strengths and missed-dose rules cannot be substituted. **What this means in India:** Use an authorised product, valid prescription and the Indian storage and disposal instructions. **How this relates to GLP-1 care:** Some GLP-1 products, including certain liraglutide formulations, use daily dosing and gradual escalation. **Safety and when to seek help:** Never share a pen, reuse a needle against instructions or double a dose after uncertainty. **Must it be taken at the same minute daily?** Follow the exact label and prescriber's plan; timing rules differ by product. ### Waist-to-height ratio Waist-to-height ratio divides waist circumference by height. It is a screening measure of central size relative to stature, not a direct measure of visceral fat. **What this means in India:** Indian risk assessment may also use sex-specific waist-circumference thresholds and other metabolic findings. **How this relates to GLP-1 care:** It can add context but does not independently determine GLP-1 eligibility or treatment success. **Safety and when to seek help:** Pregnancy, abdominal swelling and inconsistent measurement can make the ratio inappropriate or misleading. **Is one universal cut-off right for everyone?** No. Age, population, guideline and clinical context matter. ### Random blood glucose Random blood glucose is measured without requiring a defined fasting period. Interpretation depends on symptoms, recent food, illness, medicines and whether the sample is laboratory or capillary. **What this means in India:** Use the units and diagnostic criteria applied by the treating clinician and laboratory. **How this relates to GLP-1 care:** It can identify a concerning value but does not replace planned monitoring or product-specific GLP-1 care. **Safety and when to seek help:** Very high glucose with vomiting, deep breathing, confusion, dehydration or ketones needs urgent assessment. **Can a random result diagnose diabetes?** A laboratory result with classic symptoms may be diagnostic in defined circumstances; otherwise confirmation is often needed. ### Alpha cell An alpha cell is a pancreatic islet cell that produces glucagon, a hormone that helps raise blood glucose when needed. **What this means in India:** It is a physiology term, not a routine consumer test. **How this relates to GLP-1 care:** GLP-1 signalling can reduce excessive glucagon secretion when glucose is elevated. **Safety and when to seek help:** Do not use supplements claiming to repair alpha cells as a substitute for diabetes care. **Is an alpha cell the same as a beta cell?** No. Beta cells mainly produce insulin; alpha cells produce glucagon. ### Metabolic dysfunction Metabolic dysfunction is a broad description of disturbed processes such as glucose regulation, insulin action, lipid handling or energy balance. It is not one standard diagnosis. **What this means in India:** Ask which specific condition or test abnormality is meant rather than accepting a vague label. **How this relates to GLP-1 care:** GLP-1 care may address particular diagnosed conditions, not an undefined promise to reset metabolism. **Safety and when to seek help:** Severe symptoms or major laboratory abnormalities need condition-specific evaluation. **Does metabolic dysfunction always mean insulin resistance?** No. Insulin resistance may be one component among several. ### Cortisol Cortisol is a steroid hormone produced by the adrenal glands. It helps regulate stress responses, blood pressure, glucose metabolism and immune activity and follows a daily rhythm. **What this means in India:** Testing requires a defined clinical question, timing and method; one random value can be misleading. **How this relates to GLP-1 care:** Stress and sleep can affect appetite, but cortisol should not be blamed for every weight change or used to judge GLP-1 response. **Safety and when to seek help:** Rapid unexplained changes, marked weakness, easy bruising or suspected adrenal illness needs medical assessment. **Can a supplement safely reset cortisol?** Claims of a simple reset are not a substitute for diagnosis or treatment. ### Brown rice Brown rice retains the bran and germ, so it generally contains more fibre and micronutrients than polished white rice. It still provides carbohydrate and energy. **What this means in India:** It can be used with pulses, vegetables and protein in a culturally familiar balanced meal. **How this relates to GLP-1 care:** Portion, cooking, the whole meal and digestive tolerance matter during GLP-1 treatment. **Safety and when to seek help:** People with swallowing or significant digestive problems may need an adapted texture or different food. **Does brown rice prevent a glucose rise?** No. It still contains carbohydrate, though the response may differ from polished rice. ### Micronutrients Micronutrients are vitamins and minerals needed in relatively small amounts for normal body functions. Examples include iron, vitamin B12, folate, vitamin D, calcium and zinc. **What this means in India:** Needs and common food sources vary with diet pattern, age, pregnancy and health conditions. **How this relates to GLP-1 care:** Reduced food intake during GLP-1 treatment can make dietary adequacy important, but routine high-dose supplements are not automatically needed. **Safety and when to seek help:** Suspected deficiency, severe restriction or high-dose supplementation needs professional assessment because excess can also cause harm. **Can a multivitamin replace food?** No. It does not provide protein, fibre or the full food matrix. ### Sleep duration Sleep duration is the amount of time spent asleep, distinct from time in bed and sleep quality. Needs vary by age and individual context. **What this means in India:** Work shifts, caregiving, travel, heat, noise and health conditions can affect sleep opportunity. **How this relates to GLP-1 care:** Sleep can influence appetite, activity and glucose patterns, but longer sleep alone does not determine GLP-1 results. **Safety and when to seek help:** Loud snoring with breathing pauses, severe daytime sleepiness or unsafe drowsiness needs assessment for a sleep disorder. **Is eight hours mandatory for every adult?** No. Population recommendations are ranges and individual needs vary. ### Sulphur burps Sulphur burps are belches with an odour often described as rotten eggs, related to hydrogen sulphide gas. Food, slowed digestion, infection and other digestive conditions can contribute. **What this means in India:** Persistent symptoms should be assessed with food, medicine, travel and infection context. **How this relates to GLP-1 care:** They may occur alongside digestive changes during GLP-1 treatment but are not a diagnosis by themselves. **Safety and when to seek help:** Seek care for severe pain, repeated vomiting, fever, bloody or black stool, dehydration or inability to keep fluids down. **Does the smell identify the exact cause?** No. Several causes can produce a similar odour. ### Hip circumference Hip circumference measures around the widest part of the buttocks and may be used with waist circumference to calculate waist-to-hip ratio. **What this means in India:** Consistent tape placement, posture and units are needed for useful comparison. **How this relates to GLP-1 care:** It is a body measurement, not a direct measure of GLP-1 response or metabolic health. **Safety and when to seek help:** Painful swelling, a new mass or marked asymmetry needs medical assessment rather than repeated measuring. **Can hip circumference show body fat percentage?** No. It is a circumference measurement only. ### CBC A complete blood count (CBC) measures blood-cell components such as haemoglobin, red cells, white cells and platelets. It can support investigation of anaemia, infection and other conditions. **What this means in India:** Reference ranges vary by laboratory, age, sex and pregnancy context. **How this relates to GLP-1 care:** A CBC may be ordered for a clinical reason but is not a universal test of GLP-1 effectiveness. **Safety and when to seek help:** Very low haemoglobin symptoms, unusual bleeding, severe infection signs or a critical laboratory alert needs prompt care. **Does a normal CBC rule out nutrient deficiency?** No. Some deficiencies can exist before the CBC becomes abnormal. ### Individualised treatment Individualised treatment adapts decisions to the person's diagnosis, risks, other medicines, preferences, goals, access and response. It does not mean ignoring evidence or approved labels. **What this means in India:** The plan should fit Indian regulatory information, available services and the person's real circumstances. **How this relates to GLP-1 care:** GLP-1 product, dose, monitoring, nutrition and activity should be selected and reviewed for the individual. **Safety and when to seek help:** New contraindications, pregnancy, severe symptoms or major treatment changes require prompt reassessment. **Does individualised mean any requested medicine should be prescribed?** No. Safety, evidence and approved indications still apply. ### Oral contraceptive An oral contraceptive is a pill used to prevent pregnancy. Combined and progestin-only pills have different instructions, risks and suitability. **What this means in India:** Use a qualified clinician to select a method and follow the exact Indian product information. **How this relates to GLP-1 care:** Pregnancy prevention may be important during GLP-1 care. Vomiting, diarrhoea or product-specific effects on absorption may require method-specific advice. **Safety and when to seek help:** Seek urgent care for chest pain, severe breathlessness, one-sided leg swelling, sudden neurological symptoms or suspected ectopic pregnancy. **Do all GLP-1 medicines affect oral contraception in the same way?** No. Check the exact product label and clinician advice. ### Oral semaglutide in India Oral semaglutide is a prescription tablet formulation of semaglutide with product-specific dosing, administration and approved indications. It is not interchangeable dose-for-dose with injections. **What this means in India:** Verify the exact CDSCO approval, manufacturer, strength, Indian label and authorised seller. **How this relates to GLP-1 care:** Its indication may concern type 2 diabetes rather than weight management; do not infer approval from the ingredient name alone. **Safety and when to seek help:** Do not buy without a valid prescription or alter tablet timing and dose from online advice. **Is oral semaglutide the same as injectable semaglutide?** No. Formulation, dosing and instructions differ. ## Food intake Food intake is the amount and pattern of food a person consumes. Appetite, access, culture, symptoms, medicines and daily routine can influence it. During GLP-1 treatment, markedly reduced intake needs attention to overall nutrition, protein, micronutrients and hydration—not simply fewer calories. ## Subcutaneous injection A subcutaneous injection places medicine into the fatty tissue just beneath the skin. The exact injection sites, device steps, needle handling, storage and missed-dose instructions depend on the product. Training from a qualified professional and the current leaflet are safer than copying another pen's technique. ## Fat mass Fat mass is the estimated weight of fat tissue in the body. It differs from body-fat percentage, which expresses fat mass as a share of total weight. DEXA and BIA estimate fat mass using different methods, and hydration or device assumptions can affect the result. ## Time in range Time in range is the percentage of continuous-glucose-monitor readings within a defined glucose range over a chosen period. The target range and goal must be stated; they are not identical for every person, especially during pregnancy, frailty or high hypoglycaemia risk. ## Gluconeogenesis Gluconeogenesis is the production of glucose from non-carbohydrate precursors, mainly in the liver and also in the kidneys. It helps maintain glucose during fasting. In diabetes, excessive hepatic glucose production can contribute to high glucose. ## Ectopic fat Ectopic fat means fat stored in or around organs and tissues not primarily designed for fat storage, such as the liver, pancreas, heart or skeletal muscle. It is associated with metabolic dysfunction, but the relationship varies and cannot be diagnosed from BMI alone. ## Thyroid hormone Thyroid hormones, mainly T4 and T3, help regulate energy use, temperature, heart function and many other processes. Symptoms such as fatigue or weight change are not specific, so thyroid concerns require clinical assessment and appropriate tests rather than diagnosis from symptoms alone. ## White rice White rice is rice with the bran and germ largely removed. Its glucose effect depends on variety, cooking, portion and the rest of the meal. Pairing a measured portion with pulses or another protein source and vegetables can change the meal's overall nutrition and glucose response. ## Vitamin B12 Vitamin B12 supports red-blood-cell formation and nervous-system function. It is found naturally mainly in animal-derived foods and in fortified foods. Deficiency requires appropriate assessment; supplements and injections should be based on diet, symptoms, tests and clinical context. ## Sleep quality Sleep quality describes how restorative and continuous sleep feels, including ease of falling asleep, awakenings and daytime alertness. It is different from sleep duration. Persistent snoring, witnessed pauses, severe sleepiness or insomnia may need assessment rather than self-treatment. ## Reduced appetite Reduced appetite means less desire to eat. It can occur during GLP-1 treatment, but persistent inability to meet food or fluid needs, repeated vomiting, dizziness, severe weakness or rapid unexpected loss needs clinical review. Appetite suppression is not a goal at any cost. ## LDL LDL commonly refers to low-density lipoprotein cholesterol, one component of a lipid profile. Higher LDL cholesterol can contribute to atherosclerotic cardiovascular risk, but interpretation depends on overall risk, medical history, units and the laboratory method. ## Haemoglobin Haemoglobin is the oxygen-carrying protein in red blood cells. A haemoglobin result is part of a complete blood count and may help identify anaemia or other conditions. It is different from HbA1c, which reflects glucose exposure over time. ## Maintenance phase The maintenance phase is the period focused on sustaining health and weight-management gains after initial change. It may involve continued treatment, nutrition, physical activity, behavioural support and monitoring. Medicine continuation or withdrawal should be individualised because weight regain risk and approved indications differ. ## Gestational weight gain Gestational weight gain is the change in body weight during pregnancy. Appropriate gain depends on pre-pregnancy health, pregnancy course and clinical guidance. Pregnancy is not the time to pursue GLP-1 weight-loss treatment or apply a generic weight-loss target. ## Teleconsultation A teleconsultation is a clinical consultation conducted using phone, video or another permitted digital method. In India, the patient and registered medical practitioner must be identified, consent and records matter, and an in-person examination may still be needed when remote assessment is insufficient. ### Hypothalamus The hypothalamus is a small brain region that helps coordinate appetite, thirst, temperature, sleep and hormone signalling. It receives information from the body and brain, including gut and nutrient signals. GLP-1 pathways can influence appetite-related circuits, but this mechanism does not predict one person's response or establish medicine eligibility. ### Brain-gut axis The brain-gut axis is two-way communication among the brain, gastrointestinal tract, nerves, hormones, immune signals and gut microbes. It helps regulate digestion, appetite, nausea and stress responses. It is a biological system, not a diagnosis or proof that one treatment will work for everyone. ### Prefilled pen A prefilled pen is an injection device supplied with medicine already inside. Some are single-use and others contain several doses; needles, dose selection, priming, storage and disposal differ by product. Use training and the leaflet for the exact pen rather than copying another device. ### Injection pen An injection pen is a handheld medicine-delivery device. It may be prefilled, reusable, single-dose or multi-dose. Confirm the medicine, strength, dose window, needle requirements and storage before each use, and never share a pen even if the needle is changed. ### Skeletal muscle Skeletal muscle is voluntary muscle attached mainly to bones that supports movement, posture, strength and glucose use. Weight loss can include changes in fat, water and lean tissue, so preserving strength and function matters alongside the scale. ### Sarcopenic obesity Sarcopenic obesity describes obesity occurring with sarcopenia or clinically important low muscle strength and muscle quantity or quality. Neither BMI nor a consumer body-composition scale can diagnose it alone. Assessment should include function and use a stated diagnostic framework. ### Glycaemic variability Glycaemic variability means how much glucose rises and falls over time. It depends on the measurement method and period, meals, activity, illness and medicines. A single spike or a smooth-looking graph does not replace HbA1c, time-in-range context or clinical interpretation. ### Glycaemic control Glycaemic control describes how glucose is managed over time using measures such as HbA1c, fasting or post-meal glucose and, when appropriate, CGM metrics. Targets differ with age, pregnancy, frailty, hypoglycaemia risk and other conditions. ### Glycogen Glycogen is the stored form of glucose, found mainly in the liver and skeletal muscle. Liver glycogen helps maintain blood glucose between meals, while muscle glycogen mainly supports activity. Changes in glycogen also change stored water and can affect short-term scale weight. ### Glycogenesis Glycogenesis is the process of converting glucose into glycogen for storage, mainly in liver and muscle. Insulin promotes this process after food intake. It is different from gluconeogenesis, which creates glucose from non-carbohydrate precursors. ### Cardiorenal risk Cardiorenal risk is the linked risk of heart, blood-vessel and kidney disease. Blood pressure, diabetes, lipids, smoking, kidney function, urine albumin and existing disease can all contribute. It is assessed from several findings, not one score or symptom. ### Cardiometabolic health Cardiometabolic health refers to the combined state of metabolic and cardiovascular factors such as glucose, blood pressure, lipids, adiposity, activity and existing disease. A person may have risk even when one measurement is normal. ### TSH Thyroid-stimulating hormone (TSH) is produced by the pituitary gland and signals the thyroid. It is commonly interpreted with free T4 and clinical context. Weight change or fatigue alone cannot diagnose a thyroid disorder, and an abnormal result needs appropriate follow-up. ### Hypothyroidism Hypothyroidism means the thyroid does not produce enough thyroid hormone for the body's needs. Symptoms can include fatigue, cold intolerance, constipation or weight change, but they are not specific. Diagnosis relies on appropriate tests and clinical interpretation. ### Idli Idli is a steamed food commonly made from fermented rice and urad dal batter. Nutrition and glucose response depend on size, recipe, number eaten and accompanying foods. Pairing it with sambar or another protein-rich accompaniment and vegetables can change the overall meal. ### Dosa Dosa is commonly made from fermented rice and urad dal batter cooked on a hot surface. Oil, size, filling and accompaniments can vary widely. The meal should be considered as a whole rather than labelling every dosa uniformly healthy or unhealthy. ### Vitamin D Vitamin D supports calcium balance and bone and muscle health. Blood testing and supplementation should reflect symptoms, risk, diet, sun exposure and clinical context. High-dose self-treatment can be harmful and is not a routine solution for fatigue or weight change. ### Iron Iron is required for haemoglobin and many cellular functions. Plant foods, fortified foods and animal foods can contribute, but absorption differs. Fatigue alone does not prove deficiency; haemoglobin, ferritin and other findings may be needed before treatment. ### Stress management Stress management includes practical ways to reduce or cope with stress, such as problem-solving, sleep support, relaxation, activity, social connection and professional care. It can support health behaviours but does not replace treatment for anxiety, depression or another condition. ### Behaviour change Behaviour change is the process of developing and sustaining actions that support a goal. Specific, realistic steps, self-monitoring, environmental support and relapse planning are often more useful than relying on willpower or shame. ### Dizziness Dizziness can mean light-headedness, imbalance or a spinning sensation. During GLP-1 care it may relate to dehydration, reduced intake, low glucose, blood-pressure changes or another cause. Fainting, chest pain, neurological symptoms or persistent vomiting needs urgent assessment. ### Fatigue Fatigue is persistent tiredness or reduced energy that is not always corrected by rest. It can have many causes, including inadequate intake, dehydration, sleep problems, anaemia, thyroid disease, infection, mood disorders or medicine effects. Severe or persistent fatigue deserves clinical review. ### HDL HDL usually means high-density lipoprotein cholesterol, one component of a lipid profile. It participates in cholesterol transport, but a higher HDL number does not cancel the effects of LDL, triglycerides, smoking, diabetes or other cardiovascular risks. ### Triglycerides Triglycerides are a form of fat measured in blood. Results can be affected by meals, alcohol, glucose control, medicines and genetics. Very high levels can raise pancreatitis risk, so the fasting status, units and urgency should be interpreted by a clinician. ### Sodium Sodium is an electrolyte important for fluid balance, nerves and muscles. A blood sodium result is not a direct measure of how much salt someone ate; it often reflects water balance and illness. Marked abnormalities can be dangerous and require prompt assessment. ### Potassium Potassium is an electrolyte needed for nerves, muscles and heart rhythm. Kidney function, vomiting, diarrhoea and several medicines can change it. Do not start potassium supplements or salt substitutes from one result without clinical advice. ### Lifestyle intervention A lifestyle intervention is a structured plan addressing areas such as nutrition, physical activity, sleep, behaviour and support. It should be individualised, culturally practical and free from stigma. It may accompany medicine or surgery rather than being used as a test of personal worthiness. ### Medical nutrition therapy Medical nutrition therapy is nutrition care delivered by a qualified professional for a diagnosed health need. It includes assessment, an individual plan, monitoring and adjustment. It is more specific than generic healthy-eating advice. ### Postpartum weight Postpartum weight is body weight after childbirth, when recovery, fluid changes, sleep, feeding method, mental health and nutrition all matter. Rapid intentional loss or GLP-1 treatment should not be pursued from a generic target; breastfeeding and pregnancy plans require product-specific medical advice. ### Online doctor consultation An online doctor consultation is a remote clinical encounter by phone, video or another permitted method. In India, identity, consent, records and prescribing rules matter, and an in-person examination may still be necessary when remote assessment is insufficient. ### Pharmacy storage Pharmacy storage means keeping medicines within the temperature, light, security and handling conditions required before dispensing. For injection pens, cold-chain history and protection from freezing or heat can matter. A product exposed outside its stated limits should be checked with the pharmacist or manufacturer. ## References - [WHO: Obesity — GLP-1 therapies](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) - [WHO: Obesity and overweight](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight) - [Ministry of Health and Family Welfare: Prevention, screening and control of common NCDs](https://www.mohfw.gov.in/sites/default/files/Module%20for%20Multi-Purpose%20Workers%20-%20Prevention%2C%20Screening%20and%20Control%20of%20Common%20NCDS.pdf) - [CDSCO: Drugs Rules](https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/Drugs-Rules/) - [CDSCO: Bioavailability and bioequivalence](https://www.cdsco.gov.in/opencms/opencms/en/bioequi_bioavail/) - [NIDDK: Low blood glucose (hypoglycemia)](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia) - [NIDDK: Symptoms and causes of GER and GERD](https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd-adults/symptoms-causes) - [NIDDK: Prescription medications to treat overweight and obesity](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) - [NHLBI: Sleep apnea](https://www.nhlbi.nih.gov/health/sleep-apnea) - [NHLBI: Blood cholesterol diagnosis](https://www.nhlbi.nih.gov/health/blood-cholesterol/diagnosis) - [NIMH: Eating disorders](https://www.nimh.nih.gov/health/publications/eating-disorders) - [NCI: Multiple Endocrine Neoplasia Type 2](https://www.cancer.gov/publications/pdq/information-summaries/genetics/men2-hp-pdq) - [MedlinePlus: Dehydration](https://medlineplus.gov/dehydration.html) - [MedlinePlus: Bone density scan](https://medlineplus.gov/lab-tests/bone-density-scan/) - [NIA: What is menopause?](https://www.nia.nih.gov/health/menopause/what-menopause) - [WHO: Physical activity](https://www.who.int/initiatives/behealthy/physical-activity) - [NCBI MeSH: Ghrelin](https://www.ncbi.nlm.nih.gov/mesh/?term=ghrelin) - [FDA: Saxenda prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206321s020lbl.pdf) - [FDA: Mounjaro prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s041lbl.pdf) - [Endocrine Society of India: Obesity guidelines update 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12410957/) - [OSSI–ESI: India obesity-management consensus](https://pubmed.ncbi.nlm.nih.gov/42545588/) - [WHO: Guidelines on physical activity and sedentary behaviour](https://www.who.int/publications/i/item/9789240015128) - [WHO: Hypertension](https://www.who.int/news-room/fact-sheets/detail/hypertension) - [WHO: Polycystic ovary syndrome](https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome) - [Asian Working Group for Sarcopenia: 2019 consensus](https://pubmed.ncbi.nlm.nih.gov/32033882/) ## Navigation - [Browse glossary](https://blogs.sugarfitglp.com/glossary) ## Related glossary guides ### Obesity Assessment: BMI, Waist, Health and Treatment Context Query: obesity assessment India BMI waist health Obesity assessment evaluates excess adiposity and its effect on health. It should be respectful and clinically useful, combining measurements with symptoms, medical history, med... - [Obesity Assessment: BMI, Waist, Health and Treatment Context](https://blogs.sugarfitglp.com/glossary/obesity-assessment) ### Protein Intake During GLP-1 Treatment: An India-Relevant Guide Query: protein intake on glp-1 how much do you need Reduced appetite can make it harder to obtain enough protein and other nutrients during GLP-1 treatment. There is no single protein number that is right for every person. Needs... - [Protein Intake During GLP-1 Treatment: An India-Relevant Guide](https://blogs.sugarfitglp.com/protein-intake-on-glp-1-how-much-do-you-need) ### Waist Circumference for Metabolic Health: How to Measure It Query: how to measure waist circumference India Waist circumference is a tape measurement around the abdomen. It is used with other information to estimate central fat distribution and cardiometabolic risk. It does not direct... - [Waist Circumference for Metabolic Health: How to Measure It](https://blogs.sugarfitglp.com/glossary/waist-circumference) ### GLP-1 and gut health Query: GLP-1 and gut health Most people think of GLP-1 medicines as appetite suppressants or weight-loss injections. But these medicines work primarily through the digestive system, where the natural GLP-1... - [GLP-1 and gut health](https://blogs.sugarfitglp.com/glp-1-and-gut-health) ### Am I Eligible for GLP-1 in India? BMI, Conditions and Doctor Criteria Explained Query: Am I Eligible for GLP-1 in India? BMI, Conditions and Doctor Criteria Explained If you have heard about GLP-1 therapy for weight loss or blood sugar control and are wondering whether it applies to you, this guide explains the clinical criteria used in India... - [Am I Eligible for GLP-1 in India? BMI, Conditions and Doctor Criteria Explained](https://blogs.sugarfitglp.com/am-i-eligible-for-glp-1-in-india-bmi-conditions-and-doctor-criteria-explained) ### BMI criteria for GLP-1 in India Query: -BMI criteria for GLP-1 in India GLP-1 therapy is not available to everyone, and the eligibility thresholds used in India differ from those applied in Western countries. Understanding the correct BMI cutoffs fo... - [BMI criteria for GLP-1 in India](https://blogs.sugarfitglp.com/bmi-criteria-for-glp-1-in-india)